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iAbstract 
Major depressive disorder (MDD) affects millions of people every year and produces significant 
human suffering and economic burden to society. The symptomatology of MDD is heterogeneous 
and multidimensional, and only two core symptoms, depressed mood and anhedonia, are frequently 
shared by patients. Consequently, modeling of MDD is challenging, and only depression-related 
phenomena, not depressed mood itself, can be examined in animals. MDD is commonly treated with 
antidepressant drugs (or antidepressants, ADs). However, monoamine-based ADs act in a delayed-
onset manner and often exhibit only moderate clinical efficacy. Electroconvulsive therapy (ECT) 
remains the treatment of choice for treatment-resistant depression (TRD) and for cases for which a 
rapid clinical response is required. Given the practical and ethical limitations of ECT, the development 
of fast-acting ADs is needed. Importantly, the NMDA receptor antagonist ketamine has been shown 
to produce rapid and long-lasting AD effects in TRD patients. 
Changes in the levels and signaling of neurotrophin brain-derived neurotrophic factor (BDNF) 
have  been  associated  with  the  etiology  of  MDD.  However,  studies  of  genetically  modified  mice  
expressing altered levels of BDNF have not provided a solid link between BDNF deficiency and 
depression-related behavior. By contrast, emerging evidence indicates that the effects of ADs are 
mediated by BDNF and its tropomyosin-related kinase B receptor, TrkB. ADs enhance BDNF-TrkB 
signaling and thereby facilitate neuronal plasticity in the brain. Recent evidence indicates that these 
changes in plasticity lead to the restoration of juvenile-type plasticity in the adult rodent cortex, 
which allows environment-driven reorganization of brain networks. Based on these data, the 
network theory of AD action was formulated. However, it is unclear if this concept can be generalized 
to diverse neuronal networks.  
The  main  aims  of  this  thesis  were  to  investigate  the  importance  of  TrkB  signaling  in  the  
anxiety- and depression-like behavioral phenotype in mice, to examine the role of BDNF-TrkB 
signaling in the antidepressant-like effects of glutamatergic drugs in mice, to study the network 
theory of ADs in a mouse fear extinction paradigm and to investigate the behavioral effects of adult 
fluoxetine treatment in mice exposed to fluoxetine early in life.  
When examining TrkB signaling-deficient mice (TrkB.T1), we observed that young and aged 
TrkB.T1 mice exhibited alterations in their exploration and emotional behavior and increased 
behavioral despair. These findings suggest that altered TrkB signaling leads to depression-like 
behavior, and thus, TrkB.T1 mice may be used as a genetic model of depression. 
We next studied selected glutamatergic drugs in behavioral despair models and determined 
that,  similar  to  their  effects  in  humans,  ketamine  and  the  AMPA  receptor  potentiator  LY  451646  
produce an antidepressant-like effect in mice. In contrast to classical ADs, these drugs were also 
effective in BDNF heterozygote knock-out mice. Furthermore, neither of these drugs influenced 
BDNF protein or Trk-phosphorylation levels in wild-type or BDNF-deficient mice. These data suggest 
that the antidepressant-like effects of ketamine may be independent of BDNF-TrkB signaling. 
Disturbances in the serotonergic system during early development may cause permanent 
behavioral effect in adult animals. In our study, early life exposure to fluoxetine, an AD that enhances 
serotonergic transmission, led to specific and persistent behavioral changes in adult animals. 
Intriguingly, adult fluoxetine treatment normalized some of these changes. We therefore examined 
whether fluoxetine can enable plastic changes in fear circuits in mice in conjunction with an 
environmental stimulus. We observed that the combination of fear exposure and fluoxetine 
treatment produced permanent fear extinction in the classical fear conditioning paradigm in mice. 
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Importantly, neither fluoxetine nor extinction alone produced permanent fear erasure. This finding 
supports the network theory of AD action and clinical observations demonstrating the superiority of 
the combination of drug administration and psychotherapy for the treatment of post-traumatic 
stress disorder and depression. 
In conclusion, these data strengthen the connection between BDNF-TrkB signaling and the 
antidepressant-like effects of classical ADs and support the network hypothesis of AD action. In 
addition, these results also suggest that there may be fast-acting AD treatments with a mechanism of 
action that is independent of BDNF-TrkB signaling.  
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1 Introduction 
Major depressive disorder (MDD) is a substantial burden on global health; approximately 7% of 
the population in Western societies is affected by the disorder every year, and the lifetime 
prevalence is nearly 20% (Kessler et al., 2003). MDD is responsible for 5.6% of premature deaths in 
countries with high incomes and 3.4% globally (Lopez et al., 2006). Furthermore, MDD is the leading 
cause of  years  lived with disability  (YLD).  The costs  of  MDD are a  substantial  burden on the world  
economy; the annual costs of depression in Europe alone exceed 100 billion euros. Furthermore, 
MDD has devastating effects on the lives of patients and their families.   
MDD has high comorbidity with anxiety; approximately 60% of depressed patients suffer 
various symptoms of anxiety (Garcia-Toro et al., 2013; Kessler et al., 2003). Both MDD and anxiety 
are commonly treated with monoamine-based antidepressant drugs (ADs) such as the serotonin 
selective re-uptake inhibitor (SSRI) fluoxetine or the monoamine oxidase inhibitor (MAOI) 
moclobemide. However, many MDD patients (20-30%) respond poorly to current medication or 
suffer relapse after drug discontinuation (Brunoni et al., 2010; Fava, 2003). Furthermore, there is a 
delay of several weeks before ADs relieve the symptoms of MDD (Hirschfeld, 2000).  
Neurotrophin brain-derived neurotrophic factor (BDNF) and its tropomyosin-related kinase B 
receptor (TrkB) have been connected to the mechanism of action of ADs and to the pathophysiology 
of MDD (Castrén et al., 2007; Duman and Monteggia, 2006). MDD is associated with decreased BDNF 
levels, which are thought to underlie reduced neuronal plasticity, neuronal atrophy and even loss of 
synaptic connections. In contrast, ADs enhance BDNF-TrkB signaling in animal models, normalize 
BDNF levels in MDD patients and produce several neuroplastic changes in the brain. Furthermore, 
direct administration of BDNF into the rat hippocampus produces antidepressant-like behavioral 
effects. Genetically modified mice with altered levels or signaling of BDNF have also demonstrated 
the key role of BDNF-TrkB signaling in the actions of ADs, but these mouse models have not provided 
any solid link between BDNF deficiency and depression-related behavior (Castrén & Rantamäki, 
2010).
The main clinical problems associated with the use of monoamine-based ADs are their poor 
efficacy and delayed onset of action. Recent experimental evidence has provided insight into the 
neurobiological mechanism behind both of these phenomena. Specifically, ADs slowly reopen 
developmental-type plasticity in the adult rat visual cortex (Maya Vetencourt et al., 2008). This 
heightened plasticity enables environment-driven synapse reorganization within the visual cortex. 
Thus, for optimal results, ADs should be combined with adequate functional therapy. Indeed, many 
MDD patients appear to respond well when simultaneously treated with ADs and psychotherapy 
(Pampallona et al., 2004; Oestergaard & Moldrup, 2011). However, this concept has only been 
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studied in the adult rat visual cortex, and further studies are needed to generalize this finding to 
other neuronal circuits and systems.  
The delayed onset of action of current MDD therapies remains the most significant problem 
for patients at high risk of committing suicide. Electroconvulsive therapy (ECT) continues to be the 
treatment of choice for these patients. However, ECT may cause side effects, such as memory 
problems, cardiovascular changes, nausea, headache and muscle aches (Benbow, 2005). Thus, safer 
fast-acting ADs are needed. The rapid antidepressant effects of the NMDA receptor antagonist 
ketamine have recently received considerable attention in the scientific community. Interestingly, 
changes in BDNF-TrkB signaling have also been implicated in the antidepressant effects of ketamine. 
However, the mechanisms of action underlying the antidepressant effects of ECT and ketamine are 
unknown.
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2 Review of the literature 
2.1 Major depressive disorder 
Affective disorders can be divided into mania, bipolar affective disorders and unipolar 
depressive disorders (WHO, 2010). This review of the literature concentrates on unipolar depressive 
disorder, which is also known as major depressive disorder (MDD).  
Globally, MDD is one of largest burdens for health, particularly in high-income countries 
(Wittchen et al., 2011) because depression is a leading cause of disability for both women and men 
(Lopez et al., 2006). However, women are 50% more likely to suffer from depression than men. MDD 
greatly affects patients, their relatives and society. The overall burden of MDD can be divided into 
human and economic burdens.
Human suffering and changes in quality of life can be measured with the parameters YLD 
(years lived with disability) and DALYs (disability-adjusted life years), which are used to measure the 
overall  burden  of  disease  (one  DALY  represents  one  lost  year  of  “healthy”  life)  (Simon,  2003).  
Neuropsychiatric  conditions  are  responsible  for  37% of  YLD,  and MDD is  the leading cause of  YLD;  
depression causes 9.1% of total YLD in low- and middle-income countries and 11.8% in high-income 
countries  (Lopez  et  al.,  2006).  Furthermore,  MDD  is  the  seventh  leading  cause  of  DALYs  globally  
(3.4%). In high-income countries, depression is the third leading cause of DALYs (5.6%); only ischemic 
heart diseases (8.3%) and cerebrovascular diseases (6.3%) cause more DALYs than MDD. Similarly, in 
European countries, MDD is the third leading cause of DALYs (6.0%) after ischemic heart disease 
(10.1%) and cerebrovascular disease (6.8%) (Olesen & Leonardi, 2003). 
The economic burden of MDD is high; it has been estimated that the annual cost of depression 
in Europe alone is 92-118 billion euros (Andlin-Sobocki et al., 2005; Gustavsson et al., 2011; Olesen et 
al., 2012). Approximately 36-40% of this cost is direct costs, including hospitalization, medical care 
and medication; the remaining costs are indirect, such as loss of productivity (Gustavsson et al., 
2011).
Many depressed patients have suicidal thoughts, and approximately 30% have attempted 
suicide (Pawlak et al., 2013). It is estimated that 4-15% of depressed patients die of suicide (Bostwick 
&  Pankratz,  2000;  Guze  &  Robins,  1970).  For  approximately  9  of  10  suicide  victims,  some  type  of  
psychiatric disorder is an underlying cause, and 2 of 3 of suicide victims have been diagnosed with 
depression (Cavanagh et al., 2003; Henriksson et al., 1993). Thus, depression is the most significant 
risk factor for lifetime suicide (attempted) (Bernal et al., 2007); male gender and high alcohol 
consumption are other high-risk factors for suicide (Hawton et al., 2013; WHO, 2001). In addition, 
comorbidity with other psychiatric disorders, such as substance abuse and anxiety, increases suicide 
risk (WHO, 2001).  
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2.1.1 Epidemiology of depression 
Depression is a common disorder that is widely distributed through society in all ages and 
socio-economic classes in the general population. However, depression is more common in females 
than males, in young adults than elderly people and in less-educated and lower-income populations 
(Kessler et al., 2003). The lifetime prevalence of depression in the general population varies between 
1 to 19%, depending on country and culture (Kessler et al., 2003; 2005; Kessler & Bromet, 2013). In 
the USA, the lifetime prevalence of depression is 16-19%, and the 12 month prevalence is 6.6%; in 
Taiwan,  the  lifetime  prevalence  is  1.5%,  and  the  12  month  prevalence  is  0.8%  (Doris  et  al.,  1999;  
Kessler et al., 2003; 2005; Kessler & Bromet, 2013). Globally, the lifetime prevalence of depression is 
14.6% in high-income and 11.1% in low- and middle-income countries, with respective 12-month 
prevalences of 5.5% and 5.9% (Kessler & Bromet, 2013). 
2.1.2 Symptoms and diagnosis of depression 
The first descriptions of depression (lat. melancholy) in the literature are from ancient times 
(Davison, 2006). Since then, there have been many symptomatic definitions of depression, including 
depressed mood, lack of motivation, changes in appetite and weight and suicidal thoughts. In 1948, 
the World Health Organization (WHO) published the first diagnostic criteria for depression in the 
Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death (ICD-6) 
(WHO, 1948). Four years later, the American Psychiatric Association (APA) added similar criteria for 
depression to the Diagnostic and Statistical Manual: Mental Disorders, First edition (DSM-I) (APA, 
1952). Although our understanding of depression, its diversity and treatment has evolved during the 
last six decades, the neurobiological basis of depression remains unclear. 
There are two main diagnostic criteria for depression: ICD-10 and DSM-IV (WHO, 1994; APA, 
1994). Both criteria define depression in a similar way. According to the definitions, a depressive 
episode  should  last  for  at  least  two  weeks  and  include  two  of  the  following  criteria:  1)  depressed  
mood  most  of  the  time,  2)  loss  of  interest  or  pleasure  (anhedonia)  in  activities  that  are  normally  
pleasurable and 3) decreased energy (Table 1). Several additional symptoms must be present for 
diagnosis, such as suicidal thoughts, loss of confidence or self-esteem, sleep disturbances or changes 
in appetite (Gruenberg et al., 2005; Pedersen et al., 2001; Remick, 2002). The severity of depression, 
which is classified as mild, moderate or severe depression, depends on the number and clinical 
severity of these symptoms. Exclusion criteria are manic or hypomanic episodes and substance 
abuse-induced depression. 
MDD has high comorbidity with several psychiatric disorders and other diseases. Nearly 3 of 4 
(72.1%) MDD patients have a lifetime prevalence of some other DSM-IV disorder (Kessler et al., 2003). 
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Lifetime comorbidity with anxiety is approximately 50-60%, with substance use is 24-27% and with 
impulse  control  disorder  is  30%  (Fava  et  al.,  1997;  Kessler  et  al.,  2003;  Kupfer  &  Frank,  2003).  
Furthermore, the 12 month comorbidities with the aforementioned neuropsychiatric conditions are 
57.5%, 8.5% and 16.6%, respectively (Kessler et al., 2003).  
Table 1. Diagnostic criteria for major depressive disorder 
DSM IV ICD-10 
Duration of 
symptoms 
Depressed mood most of day for 
at least 2 weeks 
Depressed mood at least 2 
weeks
Symtoms 
1. Depressed mood most of the day 1. Depressed mood most of the 
day
2. Loss of interest and enjoyment, 
anhedonia
2. Loss of interest and enjoyment, 
anhedonia
3. Loss of energy or fatigue nearly 
every day 
3. Loss of energy or fatigue most 
of the time 
4. Feelings of worthlessness or 
excessive or inappropriate guilt  
4. Unfounded ideas of guilty and 
unworthniness
5. Suicidal thoughts or attemps, or 
thoughts of death  
5. Repetitive suicidal thoughts or 
attemps, or thoughts of death  
6. Reduced concentration and 
attention 
6. Reduced concentration and 
attention 
7. Psychomotor agitation or 
retardation 
7. Psychomotor agitation or 
retardation 
8. Insomnia or hypersomnia nearly 
every day 
8. Disturbed sleep
9. Altered appetite with weight 
changes (>5%) 
9. Altered appetite with weight 
changes
10. Reduced self-esteem and self-
confidence
Diagnosis Five or more symptoms, which 
should include 1 or 2. 
At least 2 symptoms from 1-3
and some from 4-10. There 
should be at least 4 symptoms 
for diagnosis mild depression 4-
5 symptoms, moderate 
depression 6-7 symptoms and 
severe depression 8-10 
symptoms (including all 1-3). 
References: APA, 1994; Gruenberg et al., 2005; Pedersen et al., 2001; Remick, 2002; WHO, 1994 
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2.1.3 Treatments for depression 
Treatments for depression vary depending on the symptoms and severity of depression. 
Standard treatments include pharmacotherapy (Table 2), psychotherapy and their combination. 
Moreover, severe and drug-resistant depression is commonly treated with ECT or transcranial 
magnetic stimulation (TMS).  
Table 2. Medical treatments of depression 
Class of antidepressants AD
Selective serotonin reuptake inhibitors (SSRI) Citalopram 
Escitalopram 
Paroxetine 
Fluoxetine 
Fluvoxamine 
Sertraline 
Tricyclic antidepressants (TCA), tertiary Amitriptyline 
Clomipramine 
Doxepin
Imipramine 
TCAs, secondary Desipramine 
Nortriptyline 
Norepinephrine reuptake inhibitors (NRI) Reboxetine
Serotonin–norepinephrine reuptake  Duloxetine 
inhibitors (SNRI) Venlafaxine
Monoamine oxidase A inhibitor (MAOI) Moclobemide 
Noradrenergic and specific Mianserin 
serotonergic ADs (NaSSA)  Mirtazapine 
Norepinephrine-dopamine reuptake inhibitors Bupropion 
Selective serotonin reuptake enhancers  Tianeptine 
MT1 and MT2 agonist, 5-HT2 antagonist Agomelatine 
Serotonin antagonist and reuptake inhibitors  Etoperidone
Nefazodone
Trazodone
References: Lam et al., 2009 
Pharmacotherapy is usually started as a monotherapy with serotonin selective reuptake 
inhibitors (SSRIs) such as citalopram, fluoxetine or sertraline (Depont et al.,  2003; Ellis et al.,  2004). 
Other possible choices include serotonin-norepinephrine reuptake inhibitors (SNRI; e.g., venlafaxine 
and duloxetine), selective norepinephrine reuptake inhibitors (NRI; e.g., reboxetine), noradrenergic 
and specific serotonergic antidepressants (NaSSA; e.g., mianserine and mirtazapine), monoamine 
oxidase A inhibitors (MAOI-A; e.g., moclobemide) and tricyclic antidepressants (TCA; e.g., imipramine, 
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desipramine and amitriptyline). Polypharmacotherapy is usually not beneficial; rather, the 
replacement of inefficacious ADs with other pharmacological classes of ADs may help.  
Psychotherapy is an effective treatment for mild and moderate depression (Ellis et al., 2004). 
However, the combination of psycho- and pharmaco-therapy usually yields more pronounced clinical 
effects than either treatment alone (Pampallona et al., 2004; Oestergaard & Moldrup, 2011). In more 
severe cases, when several pharmacotherapies combined with psychotherapy fail to relieve 
symptoms of depression, the use of ECT or TMS is considered (Brunoni et al., 2010; Ellis et al., 2004; 
Nemeroff, 2007). 
A significant number of depressed patients do not respond adequately to ADs. This medical 
condition, called treatment-resistant depression (TRD), affects approximately 30% of depressed 
patients (Olchanski et al., 2013). The widely used definition of TRD requires an unsuccessful response 
to an adequate course of treatment (Nemeroff, 2007). However, the definition of inadequate 
response has been broadly discussed in the field. Thus, Thase and Rush (1997) introduced a 5 step 
staging system for AD resistance, starting with the failure of at least one adequate trial of one major 
class of ADs (stage 1) and ending with the failure of four adequate trials of different AD classes and 
failure of a course of ECT (stage 5). The cost of TRD patients is a high economic burden for society 
and is approximately 90% higher than the cost for a non-TRD patient (Olchanski et al., 2013).  
2.2 Antidepressant drugs 
Different causes of depression have been proposed since ancient times, when depression was 
hypothesized to be caused by an imbalance of bodily fluids (Davison, 2006). At the beginning of the 
20th century, it was shown that reserpine, an antihypertensive and monoamine-depleting drug, 
causes depression-like symptoms in chronic hypertensive patients (a finding that has since been 
questioned) (Baumeister et al., 2003). In the 1950s, iproniazid, a close derivative of the tuberculosis 
drug isoniazid, was serendipitously found to recover the depressed mood of tuberculosis patients 
with depressive symptoms. Around the same time, imipramine, a tricyclic agent similar in structure 
to the antipsychotic chlorpromazin, was shown to produce antidepressant effects in psychiatric 
patients (Kuhn, 1958). Iproniazid and imipramine were subsequently shown to increase extracellular 
levels of the neurotransmitters serotonin (5-HT) and/or norepinephrine in the brain. These drugs 
inhibit either the monoamine-catabolizing enzyme monoamine oxidase (MAO) or the re-uptake 
mechanism of monoamines, leading to an increase in serotonin and norepinephrine levels in the 
synaptic cleft and enhanced serotonergic or/and noradrenergic transmission in the brain (Ashcroft et 
al., 1972; Coppen, 1967; Schildkraut, 1965). Based on these observations, the monoamine hypothesis 
of depression was introduced (Schildkraut, 1965), and all currently clinically used ADs influence the 
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monoaminergic system of the brain. However, even though biochemical responses and 
pharmacological side effects appear within hours after drug administration, the clinical symptoms of 
depression are relieved only after a delay of several weeks. This contradiction has been 
contemplated by investigators and clinicians for decades (Hindmarch, 2002). During the last two 
decades, knowledge about depression and its etiology has evolved, and novel theories have been 
introduced. The neurotrophin hypothesis of depression, which is currently one of the strongest 
theories of depression, will be discussed in greater detail. 
2.3 Neurotrophins, depression and antidepressant action  
2.3.1 Neurobiology of neurotrophins 
Neurotrophins (NTs) consist of a small family of neurotrophic factors that include nerve growth 
factor (NGF), BDNF, neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4). NTs control the 
differentiation and survival of neurons during early development (Huang & Reichardt, 2001). Later in 
adulthood, NTs regulate synaptic function and plasticity and neuronal survival (Huang & Reichardt , 
2001). NTs act through specific high-affinity tropomyosin-related kinase (Trk) receptors: TrkA for NGF; 
TrkB for  BDNF,  NT-3 and NT-4/5 and TrkC for  NT-3.  All  NTs  bind preferentially  as  pro-forms to  the 
low-affinity p75NRT receptor, which is related to controlled cell death, also known as apoptosis (Lu et 
al., 2005).  
Among  these  NTs,  the  role  of  BDNF  and  its  signaling  cascade  through  the  TrkB  receptor  in  
regulating activity-dependent neuronal and network plasticity in the developing and adult central 
nervous  system  has  been  increasingly  recognized  (Park  &  Poo,  2013;  Poo,  2001;  Thoenen,  1995).  
Neuronal activity regulates the production and release of BDNF, which plays a critical role in their 
activity-dependent plasticity. BDNF acts as a dimer and binds to the extracellular portion of the TrkB 
receptor, leading to receptor dimerization. This change induces subsequent receptor 
transphosphorylation and the phosphorylation of other intracellular tyrosine residues (Y515 and 816) 
that regulate the activation of several signaling pathways, including the Ras-MAPK (mitogen-
activated protein kinase), PI3k (phosphatidylinositol 3-kinase)-Akt (protein kinase B) and 
phospholipase C (PLC) pathways (Minichiello at al., 2009). The activation of these pathways 
regulates neuronal transmission and plasticity and the survival, proliferation and differentiation of 
cells (Figure 1). Furthermore, TrkB signaling cascades can be activated in the absence of NTs, such as 
by adenosine agonists and zinc (Huang et al., 2008; Lee and Chao, 2001; Nagappan et al., 2008).  
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Figure 1. Major TrkB-signaling-activated pathways (adapted from Minichiello, 2009). The interaction 
between the TrkB receptor and neurotrophins activates three main intracellular signaling pathways. 
Phosphorylation and recruitment of adaptors to Y515 leads to the activation of the Ras–MAPK 
signaling cascade, which leads to neuronal differentiation and growth through MAPK/ERK kinase 
(MEK)  and  extracellular  signal-regulated  kinase  (ERK)  and  to  the  activation  of  the  
phosphatidylinositol 3-kinase (PI3K) cascade, which promotes the survival and growth of neurons and 
other cells. The phosphorylation of Y816 activates phospholipase C1 (PLC1), leading to the 
generation of inositol-1,4,5-trisphosphate [Ins(1,4,5)P3] and diacylglycerol (DAG). Whereas DAG 
stimulates protein kinase C (PKC) isoforms, Ins(1,4,5)P3 promotes the release of Ca2+ from internal 
stores and the subsequent activation of Ca2+/calmodulin (Ca2+/CaM)-dependent protein kinases 
(CaMKII, CaMKK and CaMKIV). All three signaling pathways also regulate gene transcription, and 
some may be involved in long-term potentiation (LTP). BDNF, brain-derived neurotrophic factor; 
FRS2, fibroblast growth factor receptor substrate 2; GRB2, growth factor receptor-bound protein 2; 
PDPK1, 3-phosphoinositide-dependent protein kinase 1; PtdIns(4,5)P2, phosphatidylinositol-4,5-
bisphosphate; RSK, ribosomal protein S6 kinase; SHP2, SRC-homology phosphatase 2; SOS, son of 
sevenless. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience 
(Minichiello, 2009), copyright (2009). 
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2.3.2 Neurotrophin hypothesis of depression and antidepressant action  
The neurotrophin hypothesis of depression presumes that stress-induced reduction of BDNF 
signaling and neuronal plasticity causes atrophy and weakening of synaptic connections in specific 
brain areas, finally leading to altered information processing and mood disorders (Castrén, 2005; 
Duman et al., 1997; Duman & Monteggia, 2006). Furthermore, AD treatment enhances BDNF 
signaling and, in the long term, increases BDNF-mediated neuronal plasticity in the brain, facilitating 
patient recovery. Because BDNF-induced changes in plasticity take time to develop, the clinical relief 
of MDD symptoms is delayed. This hypothesis was introduced nearly two decades ago, based on 
findings that the mRNA and protein levels of BDNF in the rodent hippocampus (HC) correlate with 
depressive behaviors and anatomical changes in the HC induced by stress (Duman et al., 1997; 
Duman & Monteggia, 2006). Furthermore, Nibuya et al. (1995) observed that acute and chronic ECT 
treatment and chronic administration of ADs, including desipramine and sertraline, increased BDNF 
and TrkB mRNA levels in the rat HC.  
Acute or chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis and increases 
the synthesis and release of glucocorticoids (cortisol in humans and corticosterone in rodents) and 
corticotropin-releasing factor (CRF). Severe long term stress and hypercortisolemia can induce 
damage and atrophy in neurons of the CA3 subregion of the HC and reduce neurogenesis in the adult 
hippocampal dentate gyrus (DG), brain areas related to learning, memory and mood disorders (Fuchs 
&  Gould,  2000;  Gould  et  al.,  1997;  Gould  et  al.,  1998;  McEwen,  2000;  McKittrick  et  al.,  2000).  In  
humans, the hippocampal volume is decreased in patients suffering from MDD, most likely due to a 
decreased  number  of  synaptic  connections  (Bremner  et  al.,  2000;  Sheline  et  al.,  1996).  Similar  to  
stressed subjects, depressed patients have increased plasma cortisol levels and increased CRF levels 
in the cerebrospinal fluid (Burke et al., 2005; Merali et al., 2004). In animal studies, different stressors 
or corticoid injections decrease the expression of BDNF in the HC and prefrontal cortex, brain areas 
related to mood disorders. Altered BDNF expression levels can be reversed by both chronic ECT and 
AD treatment (Barrientos et al., 2003; Nibuya et al., 1995; Rasmusson et al., 2002; Roceri et al., 2002; 
Roceri et al., 2004). Furthermore, several clinical studies have shown that BDNF serum levels are 
decreased in depressed patients (Karege et al., 2005; Monteleone et al., 2008; Sen et al., 2008), and 
altered mRNA levels of BDNF and its TrkB receptor and lower BDNF plasma concentrations have been 
associated with suicidal subjects (Dwivedi et al., 2003; Kim et al., 2007). These findings demonstrate 
that stress and depression are correlated with altered BDNF-TrkB signaling.   
The effects of increasing and decreasing BDNF levels in the brain have been widely studied in 
animals.  Direct  injection  of  BDNF  into  the  DG  or  CA3  of  the  HC  and  midbrain  leads  to  an  
antidepressant-like effect and enhancement of the antidepressant-like effect of paroxetine in rodent 
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models of depression-like behavior (Deltheil et al., 2008; Shirayama et al., 2002; Siuciak et al., 1997). 
The tyrosine kinase inhibitor K252a blocks this effect, suggesting that the antidepressant-like 
behavior of BDNF is dependent on TrkB activity (Shirayama et al., 2002). Surprisingly, peripheral 
administration of BDNF also appears to produce antidepressant-like effects similar to those induced 
by intracranial administration (Schmidt & Duman, 2010). In contrast, direct injection of BDNF into the 
ventral tegmental area causes depression-like behavior, while blocking BDNF signaling in the nucleus 
accumbens produces antidepressant-like behavior (Berton et al., 2006; Eisch et al., 2003). A global 
reduction of BDNF expression and protein levels in the brain has not produced clear depression- or 
anxiety-like phenotypes in transgenic mice and has yielded controversial results. A summary of 
transgenic mice with altered BDNF-TrkB-signaling is described below (see chapter 2.4.6). Although 
these findings indicate a key role for BDNF in the pathology of MDD, the potential connection 
between BDNF and MDD remains unclear because the results of studies in BDNF transgenic mice 
have not been conclusive.  
A single nucleotide polymorphism (SNP) has been observed in the human BDNF gene, in which 
valine (Val) is substituted with methionine (Met) in codon 66 (Val66Met). This SNP is only observed in 
humans and is commonly expressed in the general population (Val/Met: 20-50%, Met/Met 3-20%) 
and is more common in Asian than Caucasian populations (Verhagen et al., 2008). Humans that are 
heterozygous for the Met allele display smaller hippocampal volumes and poor performance on 
hippocampal-dependent memory tasks. However, a connection between this SNP and clinical 
depression and anxiety is unclear (Gratacos et al., 2007; Verhagen et al., 2008). There is a potential 
association between Val66Met SNP and other mental disorders, such as substance abuse, eating 
disorders and schizophrenia (Gratacos et al., 2007). Chen et al. (2006) produced a mouse line with a 
knock-in  of  this  SNP.  However,  like  other  transgenic  mouse  models  of  BDNF,  these  mice  did  not  
further clarify the connection between BDNF and the pathophysiology of depression (for a further 
review, see Chapter 2.4.6). 
While the role of BDNF-TrkB signaling in the pathology of depression is unclear and 
controversial, the role of this signaling system in the effect of ADs is better characterized (Adachi et 
al., 2008; Castrén et al., 2007; Duman & Monteggia, 2006). Different classes of ADs can activate TrkB 
signaling after acute and long-term administration (Rantamäki et al., 2007; Saarelainen et al., 2003). 
Similarly, ADs, ECT and physical exercise have been shown to increase BNDF levels after several days 
of  treatment  in  animal  models  and  humans  (Chen  et  al.,  2001;  Coppell  et  al.,  2003;  Duman  et  al.,  
2008; Marais et al., 2009; Nibuya et al., 1995; Russo-Neustadt et al., 1999; Zetterstrom et al., 1998). 
Importantly, stress-induced decreases in BDNF expression and serum protein levels can be restored 
by chronic AD treatment in both experimental animals and depressed patients (Duman & Monteggia, 
2006; Nibuya et al., 1995; Sen et al., 2008). Furthermore, the presence of BDNF and the activation of 
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TrkB-related signaling are needed for antidepressant-like effects in rodents (Ibarguen-Vargas et al., 
2008; Saarelainen et al., 2003). However, the regulation of BDNF expression by ADs is more complex 
because BDNF mRNA levels have been shown to decrease shortly after AD administration in some 
studies (Coppell et al., 2003; Kozisek et al., 2008). In addition, a direct injection of BDNF into the HC 
or overexpression of full-length TrkB in the brain of transgenic mice produces antidepressant-like 
behaviors (Koponen et al., 2005; Shirayama et al., 2002; Siuciak et al., 1997).  
2.3.3 Network hypothesis of AD action 
In clinical patients, ADs relieve the symptoms of depression after several weeks of treatment. 
It has been suggested that this delay is due to the need for the growth of neuronal connections, 
neurogenesis and plasticity (Castrén, 2004; 2005). ADs enhance neuronal plasticity at many levels of 
the nervous system via a mechanism that involves BDNF signaling (Krystal et al., 2009; Maya 
Vetencourt et al., 2008). Chronic but not acute administration of ADs or ECT enhances neurogenesis 
and the survival  of  newborn neurons in  the DG of  the adult  HC,  which seems to  be important  for  
antidepressant-like behavior in rodent models (Bergami et al., 2008; Dranovsky and Hen, 2006; 
Madsen et al., 2000; Malberg et al., 2000; Santarelli et al., 2003; Wu & Castrén, 2009). Furthermore, 
ADs have been shown to specifically enhance the turnover of new neurons in the HC rather than only 
increasing their proliferation (Sairanen et al., 2005). AD treatments can also increase synaptic 
connections in the brain and in areas other than those where neurogenesis occurs (Chen et al., 2008; 
Hajszan et al., 2005; O'Leary et al., 2009). Moreover, BDNF-TrkB signaling is required for these effects 
(O'Leary et al., 2009).  
The functional significance of AD-induced plasticity changes has been recently studied in more 
detail using visual cortex (VCX) plasticity as a model platform. During early development, 
environmental stimuli direct the formation of the neuronal network in the VCX, and after a critical 
period, a permanent neuronal network is formed in the VCX (Castrén & Rantamäki, 2010). The ability 
of ADs to increase synaptic plasticity via enhanced BDNF and TrkB signaling has attracted interest in 
this phenomenon. Maffei’s and Castrén’s groups studied whether chronic fluoxetine treatment could 
open a critical period-like state and enable environment-driven reformation of the neuronal network 
(Maya Vetencourt et al., 2008). In their studies, these authors found that fluoxetine and an enriched 
environment were able to re-open developmental-like plasticity in the adult rat visual cortex (Maya 
Vetencourt et al., 2008; Sale et al., 2007).  
Closing one eye during a critical period of visual cortex development during early postnatal life 
leads to the ocular dominance of the open eye. After the critical period has closed, this dominance is 
permanent. However, chronic fluoxetine treatment can open a critical period-like state, which leads 
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to the enhanced plasticity-driven reformation of the neuronal network. Together with an 
environmental stimulus (opening the weak eye and closing the dominant eye), this reformation of 
the neuronal network recovers the vision of the weaker eye (Maya Vetencourt et al., 2008). 
Moreover, AD-induced plasticity and environmental stimuli are both required for permanent 
recovery of the vision of the poor eye. These results indicate that ADs can activate neuronal plasticity, 
which can lead to the functional reorganization of the neuronal network after the closure of the 
critical period, at least in the visual cortex of the rat (Castrén & Rantamäki, 2010). Based on these 
observations, the network theory of AD action has been formulated. 
However, some aspects of this theory are not well substantiated. Apart from the visual cortex, 
the network theory of AD action has not been tested in other neurocircuits, and data supporting its 
generalization to humans are lacking. The translation of these results to humans is challenging 
because it is impossible to control the influence of the environment. In addition, many depressed 
patients benefit only from the pharmacotherapy and do not require psychotherapy for recovery. The 
AD effect might also be mediated via other mechanisms, as some treatments (e.g., ECT and ketamine) 
have fast-acting AD effects (Li et al., 2010a). Additional studies are needed to evaluate whether this 
concept can be generalized to diverse neuronal networks and to humans. 
2.3.4 Searching for fast-acting antidepressants 
The clinical effects of classical ADs appear only after several weeks of treatment, which can be 
explained by the network hypothesis of ADs, and often are inadequate against MDD. Furthermore, 
there may be other mechanisms, independent of those specified by the network hypothesis, by 
which plasticity and information processing are enhanced. For example, ECT, the most efficacious 
antidepressant, can improve depressed mood shortly after a single treatment. However, ECT has 
unwanted side effects, and the procedure is associated with ethical concerns. Thus, there is a need 
and potential for new fast-acting and orally administrable ADs.  
There has been interest in drugs targeting brain glutamatergic signaling pathways as potential 
fast-acting  AD  candidates  (Alt  et  al.,  2006;  Skolnick  et  al.,  2009;  Vollenweider  &  Kometer,  2010).  
Several clinical studies have demonstrated that a single intravenous infusion of the non-competitive 
NMDA receptor antagonist ketamine, a dissociative anesthetic, generates a rapid and long-lasting 
antidepressant effect at a subanesthetic dose (Berman et al., 2000; Machado-Vieira et al., 2009; 
Zarate et al., 2006). An antidepressant effect of ketamine has also been observed in TRD patients 
(aan het Rot et al., 2010; Diazgranados et al., 2010; Liebrenz et al., 2007). Similarly, the NR2B subtype 
NMDA receptor antagonist traxoprodil produced a robust antidepressant effect in patients for whom 
adequate SSRI treatment had failed (Preskorn et al., 2008). 
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The behavioral effects of ketamine have been widely investigated in rodents, in which 
ketamine produces rapid and long-lasting antidepressant-like effects at a wide range of 
subanesthetic doses and enhances the responses of classical ADs (Autry et al., 2011; Koike et al., 
2011; Li et al., 2010a; Maeng et al., 2008; Popik et al., 2008; Reus et al., 2011). Similar to ketamine, 
other NMDA (N-methyl-D-aspartate) receptor antagonists have been shown to have antidepressant-
like effects and to potentiate the effects of classical ADs in rodents (Rogoz et al., 2002). Because 
ketamine and other NMDA antagonists have severe side effects and the potential for abuse, other 
glutamate-based approaches, including the potentiation of AMPA (alfa-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) receptors, have increasingly become the focus of preclinical studies. 
Allosteric modulators of AMPA receptors (AMPA potentiators) exhibit antidepressant-like effects 
similar  to  the effects  of  imipramine and ketamine (Bai  et  al.,  2001;  Li  et  al.,  2001;  Li  et  al.,  2003).  
Moreover, these AMPA potentiators enhanced the potency of classical antidepressants in preclinical 
tests of depression (Li et al., 2003). Similar to classical ADs, both NMDA antagonists and AMPA 
receptor potentiators have been shown to regulate BDNF expression both in vivo and in vitro (Autry 
et al., 2011; Garcia et al., 2008; Legutko et al., 2001; Reus et al., 2011). However, Réus et al. (2011) 
observed a dose-dependent effect of ketamine, in which the dose of ketamine was inversely 
proportional to BDNF expression levels in several brain areas. Similar effects have been observed 
with  the  AMPA  potentiator  LY  451646  (Mackowiak  et  al.,  2002).  Furthermore,  a  clinical  study  by  
Machado-Vieira et al. (2009) failed to identify an association between antidepressant response and 
serum BNDF levels in depressed patients. 
2.4 Mouse behavior in antidepressant research 
The  discovery  of  the  first  ADs  in  the  middle  of  the  20th century  initiated  a  new  era  of  
depression research. The identification of their pharmacological mechanism of action necessitated 
the measurement of the efficacy of novel AD candidates. The first methods for screening 
antidepressant effects were developed for rats in the 1960-1970s and were later introduced to mice. 
Because depression is a complex disorder with a wide spectrum of symptoms and uncertain 
biological background, modeling depression in relatively simple rodent models is challenging and 
widely criticized. Symptoms of depression and their corresponding behavioral methods are described 
in Table 3. In addition, the most common behavioral endpoints in rodent depression studies are 
presented in Figure 2 and are described in the following sections. 
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Table 3. Modelling symptoms of depression in mice 
Symptom of depression Test 
Depressed mood Cannot be monitored 
Loss of interest and enjoyment, anhedonia Intracranial self-stimulation
Sucrose preference
Social withdrawal
Loss of energy or fatigue Home cage activity
Treadmill/runnig wheel activity
Observation of nest building
Observation of sexual behavior
Unfounded ideas of guilty and unworthniness Cannot be monitored 
Repetitive suicidal thoughts or attemps, or Cannot be monitored 
thoughts of death 
Reduced concentration and attention Models of working and spatial memory:
T-maze
8-arm radial maze
Water maze
Psychomotor agitation or retardation Locomotor activity
Motor coordination 
Disturbed sleep Measurement of sleep architecture with 
electroencephalogy (EEG) 
Altered appetite with weight changes Food intake and body weight measurement
Reduced self-esteem and self-confidence Cannot be monitored 
References: Chourbaji et al. 2011, Cryan and Holmes 2005, Cryan and Mombereau 2004
2.4.1 Validity of models 
How can complex human diseases be modeled in other species? The validity of a disease 
model can be divided into three categories: face, construct and predictive validities (Belzung et al., 
2001; Willner and Mitchell, 2002; Willner & Mitchell, 2006). Face validity measures the 
phenomenological similarity of a method and a selected symptom of a human disease, without 
requiring a deeper etiological basis. Predictive validity assesses the ability of the model to predict 
changes in the human subject based upon changes in the model. Construct validity goes even deeper 
in the analysis of human disease by measuring the etiological, pathological and symptomatological 
basis of a model. For a disease model, the most important of the three dimensions is the construct 
validity. However, for a depression model, construct validity is difficult to measure.  
Review of the literature
16
Figure 2. Common behavioral endpoints in rodent depression studies (adapted from Krishnan & 
Nestler, 2010). This figure diagrams certain widely utilized quantitative and automatable behavioral 
endpoints used in experiments with rats or mice as measures of depression-related behavior. They 
can be employed following chronic stress paradigms such as social defeat, to phenotype genetic 
mutant mice, to validate antidepressant treatments or as tools to localize genomic mediators of 
complex behaviors in QTL analyses (quantitative trait locus). The most popular endpoint is immobility, 
which is interpreted as a measure of behavioral despair or freezing in response to an inescapable 
stressor like forced swimming or tail suspension. The closely related helplessness can be inferred 
through the learned helplessness paradigm, where animals receive a series of inescapable electrical 
shocks in one compartment, and on subsequent testing days display a deficit in their motivation to 
avoid these shocks when a clear escape route is provided. Anhedonia in mice and rats can be 
measured in several ways, ranging from simple measures of sucrose preference (measuring the 
relative preference for a dilute solution of sucrose versus water), to preference for a high fat diet, to 
ICSS (intracranial self stimulation) where one directly measures motivation (lever pressing) to receive 
highly rewarding electrical stimulation. Reductions in exploratory behavior are often interpreted as 
elevations in anxiety, and can be quantified by measuring amounts of time spent in aversive portions 
of a field of exploration such as the open arms of the elevated plus maze (top) or the brightly 
illuminated portion of the light-dark box. One can also measure deficits in sociability, which may 
reflect impairments in natural reward or social anxiety. These assays have been employed in stress 
paradigms, mutant mouse models as well as models of secondary depression such as that seen, for 
example,  with  obesity,  breast  cancer  or  chronic  interferon  treatment.  A  common  practice  is  to  
generate behavioral profiles by employing a broad battery of these tests following stress, genetic, or 
pharmacological manipulations, which can also include changes in weight and appetite, as well as 
deficits in self-grooming (deteriorations in fur coat). Reprinted with permission from the American 
Journal of Psychiatry, (Copyright ©2010).  American Psychiatric Association. 
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Criteria for face validity. Face validity compares similarities between symptoms and signs of a 
disorder and the model (Belzung et al., 2001; Willner et al., 2002; Willner & Mitchell, 2006). 
Depression is expressed in various ways in MDD patients, and symptomology can differ from patient 
to patient. However, not all symptoms are equal; some main symptoms have higher weight than 
others. The most important symptoms of depression include decreased mood, feelings of 
worthlessness and thoughts of death or suicide and are impossible to model in animal experiments. 
However, many depressed patients usually lose their interest in daily satisfying activities, e.g., eating, 
drinking and engaging in sexual activity and social contact, that were previously pleasurable to the 
subject. This anhedonic behavior can be measured in rodents in a test based on sucrose preference. 
Furthermore, some patients experience changes in appetite and weight; both of these phenomena 
can be measured in mice with metabolic cages and scales, respectively. In addition, insomnia or 
disruptions in sleep can be modeled in mice directly by monitoring the characteristics of their sleep 
by electroencephalogram or indirectly by following mouse circadian rhythms. Moreover, fatigue and 
loss  of  energy  can  be  measured  in  mice  via decreased  locomotor  or  running  wheel  activity  or  
disruptions in nest building. These examples illustrate the diversity of symptoms of depression and 
the difficulty of modeling them. Furthermore, to induce behavioral changes in naïve animals, some 
instigator is needed; in AD research, stress is usually used to trigger abnormal behavior. In addition, 
to obtain adequate face validity for depression, tests and models should include responsiveness to 
common ADs, preferably under chronic administration.  
Criteria for predictive validity. The predictive validity of a depression model is determined 
mainly by the responsiveness to AD treatment (Belzung & Griebel, 2001; Willner et al., 2002; Willner 
and Mitchell, 2006). A model should respond to commonly used ADs (true positive; SSRIs, TCA, 
MAOIs, SNRIs, ECT) and show negative results for clinically ineffective compounds (true negative). 
Furthermore, good predictive validity also requires the minimization of false-positive (compounds 
showing a response in the model but with no clinical effectiveness) and false-negative compounds 
(compounds showing no response in the model but with clinical effectiveness). In practice, it is 
impossible for a depression model to detect 100% of the clinically effective AD treatments because 
the clinical efficacy of some compounds is unclear. Moreover, there is great heterogeneity in the 
responses of MDD patients to AD treatments (Willner & Mitchell, 2006). It is generally accepted that 
a reliable depression model should respond to the chronic administration of several classes of ADs 
(SSRI, TCA, MAOI, SNRI) and ECT and should not respond to psychostimulants, anticholinergics, 
opiates or benzodiazepines (Willner & Mitchell, 2006). Responsiveness to the chronic administration 
of ADs increases the predictive validity of a depression model; good examples of depression models 
sensitive to chronic but not acute administration of ADs are chronic mild stress and olfactory 
bulbectomy tests (Harkin et al., 2003; Muscat et al., 1992; Papp et al., 1996; Strekalova et al., 2006). 
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Criteria for construct validity. Construct validity includes similarities both in symptoms and in 
the etiological basis of the disease (Belzung & Griebel, 2001; Willner et al., 2002; Willner & Mitchell, 
2006). For good construct validity, a depression model should mimic the pathological state of MDD 
induced by the cause of the clinical disorder. However, variable factors (e.g., stressful life events, 
heredity and internal causes) can increase the vulnerability to MDD, with no single factor as a cause 
of depression (Tennant, 2002). Some biochemical and anatomical changes, such as disruption of the 
HPA axis and decreases in hippocampal volume and brain monoamine and BDNF levels, have been 
connected to the pathophysiology of depression. Moreover, the pathogenesis of depression is more 
likely due to an accumulation of a number of different risk factors. However, as long as the etiology 
of depression remains unclear, the construct validity of any model of depression is relatively poor. 
2.4.2 Tests measuring antidepressant efficacy 
Early methods for measuring antidepressant effects were mainly based on the monoamine 
hypothesis and thus measured monoamine dysfunction in the brain. One of these methods measures 
hypothermia induced by reserpine or apomorphine, which can be reversed with tricyclic ADs 
(Alpermann et al., 1992). These methods measure more pharmacological effects of ADs than 
modeling depression, and they have relatively good predictive validity when tested with classical ADs 
but poor or no face or construct validity.  
In the 1960s-1970s, models of behavioral despair were developed. In these models, which 
were first designed with rats and subsequently modified for mice, rodents are exposed to an 
inescapable and unpredictable stress, which is said to model depression. In the learned helplessness 
(LH) model, mice are placed in a chamber from which they are unable to escape and exposed to 
inescapable and unpredictable shocks (Kudryavtseva et al., 1991). Repeated exposure to the shocks 
leads to the despair behavior, including vocalization and passivity and alteration of sleep-wake 
patterns. Later, when tested in escapable conditions, LH-treated mice fail to escape shock even when 
escape is possible; this response is considered behavioral despair. Chronic AD (imipramine) 
treatment reduced this behavior to the control animal level (Kudryavtseva et al., 1991). 
Another method of inducing behavioral despair is the forced swimming test (FST), which was 
first introduced by Porsolt et al. (1977). In this model, mice are placed in a glass cylinder filled with 
water so that they cannot reach the bottom of the cylinder or climb out of it. Initially, the mice swim 
and attempt to climb out of the cylinder. After a few minutes, the mice begin to float and become 
immobile. Immobility of mice is considered a despair behavior, which can be reversed by acute 
administration  of  ADs  (Petit-Demouliere  et  al.,  2005;  Porsolt  et  al.,  1978).  Another  model  of  
behavioral despair, the tail suspension test (TST) modified from the FST, was subsequently 
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introduced (Steru et al., 1985). Similar to the FST, mice are placed in an inescapable situation; in this 
test, the mice are hung by their tails from a hook, and the immobility time is measured. However, 
there are several differences between the FST and TST, apart from their notable similarities (Cryan et 
al., 2005). Unlike the FST, in the TST, mice are not required to have the ability to swim, which may be 
impaired in some genetically modified mice. Another advantage of the TST is that, contrary to the 
FST, it does not cause hypothermia in mice. There are also differences between the FST and the TST 
in their ability to differentiate classes of ADs (Cryan et al., 2005). Traditionally, it was presumed that 
SSRIs do not have antidepressant-like effects in the FST, but SSRIs have been shown to be effective in 
TST  (Cryan  et  al.,  2005).  However,  the  selection  of  the  mouse  strain  may  strongly  influence  the  
effectiveness of ADs (Lucki et al., 2001; Petit-Demouliere et al., 2005). Furthermore, baseline 
immobility in both the FST and TST may vary widely depending on the genetic background of the 
strain (Bai et al., 2001). Measuring immobility or other behaviors subjectively is challenging and can 
be easily biased; thus, validated and automated recording systems are recommended for both the 
FST and TST (Crowley et al., 2004; Hayashi et al., 2011; Juszczak et al., 2008). 
ADs and ECT decrease the immobility  of  mice in  these tests.  Furthermore,  stressors,  such as  
immobilization, foot shock and social defeat, increase the depression-like behavior of mice in the FST 
(Hebert  et  al.,  1998).  The  FST  and  TST  are  also  used  to  measure  depression-like  behavior  after  
chronic mild stress in a model system. Although despair models reveal remarkable antidepressant 
effects, they have poor validity as depression models. One of their major disadvantages is that ADs, 
which work in depressed patients only after several weeks of treatment, have an acute effect in this 
model. Another substantial drawback of these methods is that the mice used in these tests are 
usually naïve, and behavioral despair is induced by short-term stress lasting only minutes. However, 
all ADs in clinical use exhibit antidepressant-like effects in these models. Thus, these tests do not 
accurately model depression but could be used to measure antidepressant efficacy. 
2.4.3 Tests based on anhedonic behavior 
Many depressed patients lose interest in daily satisfying elements (e.g., food, drink, sex and 
social contacts) that previously were pleasurable to the subject. This anhedonic behavior can be 
measured in rodents in a test based on sucrose preference (Forbes et al.,  1996; Papp et al.,  1996). 
Mice are naturally more interested in sweet solutions when given free choice between ordinary tap 
water and a sweet sucrose solution. Furthermore, when animals are stressed, they lose their interest 
in the sweet, pleasurable sucrose and consume equal volumes of water and sucrose solution (Forbes 
et al., 1996; Papp et al., 1996). Furthermore, as social interactions are typical for humans and mice, 
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social withdrawal can be considered together with other chronic stressors as a relevant trigger for 
this behavior.  
Along with the sucrose preference test, other reward-based methods can be used to measure 
anhedonia. One example of these methods is the intra-cranial self-stimulation test, in which rodents 
are trained to self-stimulate with pleasurable electrical intracranial stimulation (Slattery et al., 2007). 
Chronic mild stress increases the threshold in this test, and chronic administration of ADs can recover 
these changes in the threshold (Fibiger & Phillips, 1981). However, this test is mostly used in 
addiction studies, and its use of it in AD studies may be not be appropriate. 
2.4.4 Tests measuring emotional and fear behavior of mice 
Because depression is often comorbid with anxiety in clinical patients and both disorders are 
treated with ADs (Borsini et al.,  2002), it  is relevant to also measure anxiety-like behaviors of mice. 
However, the symptoms of depression and anxiety are commonly mixed, and the interpretation of 
these models is difficult.  
Classical methods to measure anxiolytic-like behavior are based on conflicts in mouse 
emotional behavior. Mice naturally explore novel areas, and when placed in a new, unsafe 
environment,  they  are  faced  with  a  conflict  between  their  natural  urge  to  explore  new  areas  and  
threat from a menacing territory. When these mice are given an anxiolytic compound, they explore 
more in the threatening environment. Classical examples of this type of test are the open field (OF), 
the elevated plus maze (EPM) and the light/dark exploration (LD) tests. In the OF, the mouse is 
placed in an open, brightly illuminated round- or square-shaped area, and the exploration behavior 
of the mouse is observed (Walsh & Cummins, 1976). This test measures both anxiety-like behavior 
(time spent  in  the central  portion of  the area)  and overall  locomotion (total  distance traveled and 
vertical activity) of the mice. In the EPM, the mouse is placed in a piece of equipment shaped like a 
cross, with two open arms and two arms with walls, that is elevated from the ground (Hogg, 1996; 
Montgomery,  1955).  The mouse is  placed in  the middle  of  the maze,  and the latency to  the open 
arms, time spent in the open arms and the total arm entries are measured. The LD test is performed 
in a test box including two compartments, one of which has black walls and a cover and the other of 
which is brightly illuminated (Bourin & Hascoet, 2003). The mouse is positioned in the bright side of 
the apparatus, and the latency to the dark compartment, time spent in both compartments and 
transitions between compartments are measured. All of these tests are sensitive to anxiolytics, e.g., 
diazepam and alcohol. However, these tests are also sensitive to treatment-induced changes in 
mouse locomotion, e.g., amphetamine-induced hyperactivity causes false-positive results in this test. 
Thus, other methods are also used to measure anxiety-like behavior. 
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There are several tests that measure anxiety-like behavior independent from locomotor 
activity. In the novelty suppressed feeding (NSF) test, the mouse is subjected to fasting and is 
subsequently placed in an open, brightly lit area with a small piece of food in the middle (Dulawa & 
Hen, 2005; Hodes et al., 2010). Normally, the novel environment inhibits the mouse from eating the 
food. When treated with an anxiolytic compound (e.g., diazepam), the latency is decreased. Acute 
fluoxetine and TCA treatments do not have any effects, but chronic treatment produces anxiolytic 
effects in this model (Borsini et al., 2002; Dulawa & Hen, 2005; Hodes et al., 2010). Another simple 
and widely used test is the marble burying (MB) test, in which glass marbles are placed in the home 
cage of an individual mouse (De Boer & Koolhaas, 2003; Nicolas et al., 2006). Mice tend to cover all 
marbles, and anxiolytic compounds reduce this burying behavior. SSRIs, TCAs and many other ADs 
produce anxiolytic-like behavioral changes in this test when administered acutely and, for some ADs, 
when administered chronically (Borsini et al., 2002). However, this test has been criticized because it 
is more likely to measure stereotypical or compulsive behavior than anxiety-like behavior of mice 
(Thomas et al., 2009). Stressful handling (e.g., insertion of a rectal probe) induces hyperthermia in 
mice (Adriaan Bouwknecht et al., 2007). This increased body temperature can be normalized with 
anxiolytic drugs. However, ADs do not appear to have any effect on this model (Adriaan Bouwknecht 
et al., 2007; Borsini et al., 2002).   
Mice are naturally interested in seeking novel environments and objects. This characteristic 
can be exploited to measure xenophobia and anxiety-like behavior in mice in the novel object 
recognition  test  (NOR)  (Sik  et  al.,  2003).  Mice  are  introduced  to  two  objects  for  a  period  of  time.  
These objects are removed and replaced by two objects, a familiar object and a new object. Mice are 
normally more interested in the new object than the familiar one. Mice that spend less time 
investigating the novel object are considered to have anxiety-like behavior, whereas mice that spend 
more time with the new object exhibit anxiolytic behavior. However, this test is also used to measure 
the  working  memory  of  the  animal,  and  interpretation  of  the  test  can  be  challenging.  Clearly,  
complementary behavioral and biochemical data (e.g., cortisol levels) could strengthen the 
interpretation. 
In threatening situations, mice have a natural tendency to either escape or freeze. In 
inescapable situations, mice are considered as freezing when they do not move other than breathing. 
In a classical model of fear conditioning (FC), mice are subjected to a conditioned stimulus (CS; e.g., 
sound) and, simultaneously, to an unpleasant, unconditioned stimulus (US; e.g., electric foot shock) 
(Myers & Davis, 2007). Subsequently, the mice freeze when presented with the CS. After the 
conditioning, anxiolytic compounds decrease the freezing time of mice. The effects of ADs in this 
model are variable; SSRIs have acute anxiolytic effects, whereas other classes of ADs have small or no 
effects on FC (Borsini et al., 2002). Similarly, chronic administration of ADs has varying anxiolytic 
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effects on freezing behavior (Borsini et al., 2002; Burghardt & Bauer, 2013). Furthermore, after the 
conditioning, the cued and contextual memory of mice can be measured. In the cue memory test, 
the mouse is placed in the novel context, and fear-response-related memory (freezing time during 
the CS) is assessed; the context-related anxiety-like memory can be measured in a familiar context in 
the absence of the CS. 
Fear responses can be erased with extinction training, which includes repeated appearance of 
the  CS  in  the  absence  of  the  US  (LeDoux,  2000;  Milad  et  al.,  2006;  Myers  &  Davis,  2007).  After  
extinction training, the freezing of mice in the presence of the CS is equal to the freezing time before 
conditioning. However, the effect of extinction training is short lived, and the fear response to the CS 
is recovered after some time. This phenomenon is called spontaneous recovery. Fear response can 
also be evoked with repeated appearance of the CS after the fear extinction in the original context 
(fear renewal). Extinction and spontaneous recovery are performed in a different context than that in 
which the conditioning was performed to prevent an influence of the conditioning context. 
Interestingly, extinction training in juvenile mice induces permanent fear erasure (Gogolla et al., 
2009).
2.4.5 Depression models based on stress 
There is strong evidence that stressful life events and depression have a considerable 
connection; up to 80% of depressed patients have had a major negative life event (Mazure, 1998). 
Most studies have identified episodic stressors (stressors with a beginning and end) as the factor 
most strongly connected to depression (Hammen, 2005). In general, these stressors are usually 
related to interpersonal loss/separation or the threat of them, particularly in women (Paykel, 2003; 
Tennant, 2002). Moreover, the secretion of the stress-related hormone cortisol is increased by 50% 
in depressed patients (Checkley, 1996), emphasizing the association between stress and depression. 
Chronic mild stress. To mimic the connection between stressful events and depression, the 
chronic mild stress (CMS) procedure was introduced. In CMS, rodents (mice or rats) are exposed to 
unpredictable, mild environmental stressors for several weeks (Forbes et al., 1996; O'Neil & Moore, 
2003; Papp et al., 1996; Strekalova et al., 2004; Strekalova et al., 2011). These stress factors can be 
social or physiological and vary from species to species. For rats and mice, stressors may include the 
following: wet bedding, disrupted dark-light circle, water and food deprivation/restrictions, 
immobilization (positioned in a small tube) and tilting of the cage at an angle (Pothion et al.,  2004; 
Smirnov et al., 2013). However, some stressors, including exposure to a rat (for mice) or suspension 
of mice by the tail, may not be considered mild stressors but are still widely used in stress models 
(Strekalova et al., 2004). Chronic exposure to these stressors leads to anhedonia and other 
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depression-related behaviors (e.g., increased immobility in the FST or alterations in aggression, 
grooming and sexual behavior) in mice (Enkel et al., 2010; Mineur et al., 2003; Willner, 2005), which 
can be reversed by AD treatment (Muscat et al., 1992; Papp et al., 1996; Strekalova et al., 2006). CMS 
also increases  the activity  of  the HPA axis  and hypersecretion of  corticosterone (Vollmayr  & Henn,  
2003). There are some drawbacks and concerns about this model; the stressors employed vary 
greatly depending on the laboratory, and reproducibility between laboratories is poor. Furthermore, 
the  interstrain  variability  of  sensitivity  to  CMS  is  high  (Ibarguen-Vargas  et  al.,  2008;  Mineur  et  al.,  
2003;  Pothion  et  al.,  2004).  However,  a  few  requirements  are  essential  to  ensure  success  in  this  
model with mice, including the need for multiple changing stressors that occur in unpredictable 
orders  and  intervals.  The  validity  of  CMS  is  relatively  good;  mice  exposed  to  stressors  exhibit  
anhedonia, decreased activity and sexual behavior, altered sleep patterns and loss of weight 
(Vollmayr  &  Henn,  2003).  Furthermore,  all  major  AD  treatments,  including  ECT,  work  in  the  CMS  
model when administered chronically, thus increasing the predictive validity of this model (Muscat et 
al.,  1992; Papp et al.,  1996; Strekalova et al.,  2006). Some biochemical changes (e.g.,  alterations in 
norepinephrine and serotonin systems) and changes in the HPA axis similar to those observed in 
human depression are also observed in this model.  
Olfactory bulbectomy. Smell is the most important sense for rodents because it mediates 
messaging by pheromones and carries information about the behavioral and physiological status of 
an animal, social recognition, breeding and aggression behaviors (Shepherd, 2006). The loss of the 
sense of smell isolates a rodent from its psychosocial milieu, causing stress and behavioral and 
biochemical changes in animals. This phenomenon was used to construct the olfactory bulbectomy 
(OB) model of depression. In this model, rodents (mice or rats) are subjected to bilateral lesions of 
the olfactory bulbs. This procedure leads to anosminia, or loss of the sense of smell, causing long-
lasting behavioral changes related to depression-like behaviors. These changes include abnormal 
sleep patterns, agitation, weight loss and changes in hedonic behavior (Liebenauer & Slotnick, 1996; 
Song & Leonard, 2005). Furthermore, OB increases the exploration and hyperactivity of rodents in an 
OF  test  (Zueger  et  al.,  2005).  This  change  can  be  reversed  by  chronic  but  not  acute  AD  treatment  
(Freitas et al., 2013; Machado et al., 2012). OB appears to have good predictive validity because all 
classes of therapeutically active ADs yield positive results in this model when administered 
chronically (Harkin et al., 2003). In contrast, psychotropic drugs, which lack antidepressant activity, 
fail to reverse these behavioral changes. OB induces alterations in neurochemical, 
neuroendocrinological and neuroimmunological indicators that also can be reversed by chronic AD 
treatment (Roche et al., 2007). 
Early life stress. Rodents and humans are social animals, and separation from other members 
of their species causes behavioral changes, such as depression in humans. In particular, adverse early 
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life experiences and stress significantly increase susceptibility to mental diseases, including 
depression (Newport et al., 2002). To model dysfunctional parenting, pups are separated from their 
mother for designated periods of time, usually during the first 2-3 postnatal weeks. Repeated 
deprivation of their mother decreases the maternal care of the pups, which is critical for mental and 
physical development. Thus, maternal separation (MS) increases anxiety and depression-like 
behavior in rodents (Millstein & Holmes, 2007). Neonatal stress induced by MS also causes changes 
in the HPA axis activity, leading to elevated corticosterone levels and decreases in hippocampal BDNF 
and neurogenesis in mice (Kikusui et al., 2009). In addition, AD treatment during the early postnatal 
period has been shown to produce long-lasting changes in depression- and anxiety-like behavior, 
which can be used to model depression (Ansorge et al., 2004; Vogel et al., 1990). 
Social stress. Stress can be induced not only by social separation but also by subjecting animals 
to chronic social defeat (SD). The SD model includes daily exposure to a novel, physically superior 
aggressor for a defined period of time. This exposure leads to avoidance of social interaction, 
anhedonic behavior and increased anxiety-like behavior in the defeated mice (Buwalda et al., 2005; 
Strekalova et al., 2004; Tsankova et al., 2006). Furthermore, SD increases plasma corticosterone 
levels and decreases hippocampal BDNF levels. Similar to OB, the changes caused by SD can be 
reversed  by  chronic  but  not  acute  administration  of  ADs  (Tsankova  et  al.,  2006).  The  social  
interaction of mice can be measured in a resident-intruder test, in which a mouse (resident) is placed 
in a cage and can explore, thus familiarizing itself with the cage. Once the mouse becomes familiar 
with the cage, an intruder mouse is introduced, and aggressive and social contacts are counted.  
2.4.6 Genetic mouse models of depression 
Since the production of the first genetically modified mice, there has been a rapid increase in 
the number of transgenic mice established to model depression. Research on genetic models of 
depression has focused on monoamines and their metabolism, particularly serotonin (Fernandez & 
Gaspar, 2012; Gardier et al., 2009; Gardier, 2009). Other approaches have also been employed; for 
example, glucocorticoid receptor-impaired mice exhibit antidepressant-like behavior, whereas 
endocannabinoid CB1 receptor-deficient mice exhibit increased anxiety- and depression-like 
behavior (Cryan et al., 2002; Valverde and Torrens, 2012). Furthermore, mice overexpressing the CB2 
receptor have a depression-resistant endophenotype (Garcia-Gutierrez et al., 2010). The introduction 
of the neurotrophin hypothesis of depression led to an increased number of transgenic mice related 
to NTs and particularly to BDNF. However, as long as the etiology of depression remains uncertain, a 
conclusive genetic model cannot be introduced. (Cryan et al., 2002; Gardier et al., 2009)  
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The serotonin transporter (SERT/5-HTT) plays a key role in the function of serotonergic 
neurons. SERT terminates synaptic transmission of serotonin by re-uptaking serotonin into the 
presynaptic neuron (Daws, 2009). Inhibition of SERT with an SSRI (e.g., fluoxetine) increases the 
concentration of serotonin in the synaptic cleft, leading to increased neuronal transmission. For 
decades,  this  pathway has  been considered to  play  a  key role  in  the mechanism of  action of  ADs.  
Total deletion of SERT in transgenic mice leads to a depression- and anxiety-like phenotype and sleep 
disturbances; these mice exhibit increased immobility time in the FST and TST; increased anxiety-like 
behavior in the EPM-, LD- and OF-tests; decreased locomotor activity and increased REM sleep 
(Alexandre et al., 2006; Holmes et al., 2003b). Similar changes in behavior are observed when wild-
type (WT) or SERT(+/-) mice  are  exposed  to  SSRIs  (e.g.,  fluoxetine  or  citalopram)  during  the  early  
postnatal state (Ansorge et al., 2004). This contradictory effect of early life exposure is hypothesized 
to be due to disrupted activation of the presynaptic autoreceptor of serotonin, the 5-HT1A-receptor; 
administration of the highly specific 5-HT1A receptor antagonist WAY100635 in the early postnatal 
period and in adulthood reverses the behavioral changes induced by genetic SERT depletion 
(Alexandre  et  al.,  2006;  Holmes  et  al.,  2003c).  Furthermore,  SERT  plays  an  important  role  in  the  
mechanism of antidepressant action of SSRIs in the FST and TST; the antidepressant effects of the 
SSRI fluoxetine but not the noradrenergics imipramine or desipramine are blunted in SERT knockout 
(KO) mice (Holmes et al., 2002). However, there appears to be some changes in the behavioral 
phenotype of SERT-KO mice depending on their genetic background (Holmes et al., 2002; Holmes et 
al., 2003a).  
Because the 5-HT1A receptor is involved in the antidepressant-like effects of SSRIs, 5-HT1A-KO 
mice have been examined in tests measuring anxiety- and depression-like behavior. These mice 
displayed a paradoxical behavioral phenotype characterized by increased avoidance of open and 
threatening areas in the EPM and OF and decreased immobility time in the FST, indicating increased 
anxiety- and decreased depression-like behavior (Heisler et al., 1998; Parks et al., 1998). Moreover, 
many mice with modifications in genes related to the synthesis, release and re-uptake of 
neurotransmitters have been created, but most lack clear depression- or antidepressant-like 
behavioral phenotypes (Fernandez & Gaspar, 2012). 
After the introduction of the neurotrophin hypothesis of depression in the 1990s, the focus of 
depression research turned to the NTs and, in particular, to BDNF. Several transgenic mice have been 
created with a modulation in BDNF expression. At the beginning of the 1990s, Ernfors et al.  (1994) 
created a mutant mouse lacking BDNF in the brain, a constitutive BDNF KO. Mice lacking both BDNF 
alleles  have  severe  health  problems  and  die  during  the  first  weeks  of  life  (Ernfors  et  al.,  1994).  
However, heterozygous BDNF KO (BDNF(+/-)) mice are vital, appear normal and display BDNF mRNA 
and protein levels in the brain that are reduced by half when compared to their littermate WT 
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controls (Ibarguen-Vargas et al., 2009; Korte et al., 1995; MacQueen et al., 2001). BDNF(+/-) mice have 
been widely studied, and their behavioral phenotype has been quantified, although results vary 
among laboratories    (Table  4).  These mice have been shown to have increased appetite  and gain  
weight  easily  (Chen  et  al.,  2006;  Kernie  et  al.,  2000;  Lyons  et  al.,  1999).  They  have  normal  visual,  
auditory and nociceptive senses but have some impairment in the olfactory system (Bath et al., 2008; 
Liu et al., 2004). Most of the studies found no differences in locomotor activity in OF or novel cage 
tests when compared with the control group (Chen et al., 2006; Chourbaji et al., 2004; Ibarguen-
Vargas et al.,  2009; Li  et al.,  2010b; Lyons et al.,  1999; MacQueen et al.,  2001; Psotta et al.,  2013). 
However, Kernie et al. (2000) observed a significant reduction in the activity of these mice. BDNF(+/-) 
mice  have  impaired  contextual  memory  in  the  Morris  water  maze  and  FC  test,  but  their  cued  
memory is intact (Chen et al., 2006; Linnarsson et al., 1997; Liu et al., 2004); however, not all studies 
are in agreement on this issue (Chourbaji et al., 2004). These mice also appear to have impaired fear 
extinction behavior in the FC paradigm (Psotta et al., 2013). The anxiety- and depression-like 
behaviors of BDNF(+/-) mice appear to be more complex. Some experiments have revealed no changes 
in anxiety-like behavior (Chourbaji et al., 2004; Ibarguen-Vargas et al., 2009), whereas others have 
observed increased aggressiveness and anxiety-like behavior (Chen et al., 2006; Li et al., 2010b; Lyons 
et al., 1999). Furthermore, these mice do not appear to have depression-like behavior in the FST or 
TST test (Chourbaji  et al.,  2004; Duman et al.,  2007; Ibarguen-Vargas et al.,  2009; MacQueen et al.,  
2001; Saarelainen et al., 2003), but they have increased latencies to escape in LH (MacQueen et al., 
2001). In contrast, stressful experiences appear to trigger anxiety- and depression-like behavior in 
BDNF(+/-) mice (Carola & Gross, 2010; Duman et al., 2007). Moreover, the effects of ADs are blocked 
in these mice when tested in the FST or TST (Ibarguen-Vargas et al., 2009; Saarelainen et al., 2003). In 
conclusion, BDNF(+/-) mice gain more weight, are more aggressive and learn and remember less well 
than their littermate WT controls. These animals do not exhibit clear anxiety- or depression-like 
behaviors  but  are  more vulnerable  to  stress.  Furthermore,  the effects  of  ADs are  blocked in  these 
mice. 
Because the behavioral phenotype of the constitutive BDNF(+/-)-KO mouse is vague and new 
advances in gene technology have been introduced, additional genetically modified mice have been 
generated,  that  focus  on  the  expression  of  BDNF  (Table  5).  Rios  et  al.  (2001)  produced  two  
conditional BDNF KO mouse lines by crossing mice carrying the floxed BDNF (flBDNF) allele with 
another line expressing Cre recombinase under the direction of the -calcium/calmodulin-dependent 
protein kinase II (CamK) promoter, which drives expression in post-mitotic neurons. Two mouse lines, 
CamK-cre93 and CamK-cre159, were created from the KO starting from postnatal day 21 and 15, 
respectively. Both of these lines displayed increased food intake, weight gain, anxiety-like behavior 
and hyperactivity (Rios et al., 2001). Similar to the study by Rios et al., Monteggia et al. (2007)  
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generated two conditional  BNDF KO mice lines.  One line was constructed by crossing flBDNF mice 
with a line containing Cre-driven human glial fibrillary acidic protein (GFAP)-Cre, while the other was 
created by crossing flBDNF and CaMKII-Cre transgenic mice. GFAP-Cre mice express Cre recombinase 
in broad forebrain regions during late embryogenesis, whereas the CamKII-Cre mice express the Cre 
recombinase in similar regions during postnatal development (Monteggia et al., 2007). CaMKII-
CrexflBDNF mice exhibit a significant reduction of BDNF mRNA levels in the HC and dorsal cerebral 
cortex, while GFAP-CrexflBDNF mice lack BDNF mRNA almost completely in the same brain areas. In 
behavioral analyses, Monteggia et al. (2007) observed that male conditional KOs in both lines had 
hyperactivity but normal depression-like behavior. By contrast, female mice had normal activity but 
increased depression-like behavior. Furthermore, the antidepressant effect of desipramine was 
blunted in both male and female conditional BDNF KO mice.  
Another approach to create time-dependent KO mice is to use an inducible KO method. In this 
procedure, a pharmacological compound, e.g., tamoxifen or doxycycline, is used to either activate or 
block gene expression. Monteggia et al. (2004) produced trigenic mice in which BDNF expression was 
knocked  out  in  the  absence  of  doxycycline.  In  these  mice,  early  KO  of  BDNF  led  to  a  hyperactive  
phenotype with impaired contextual and cue memory. In contrast, the adult KO had a milder 
phenotype, with some impairment in contextual memory. Autry et al. (2009) subsequently examined 
the influence of chronic unpredictable stress (CUS) on similar mice. These authors observed that 
female mice with induced BDNF KO were more vulnerable to CUS-induced anxiogenic and anhedonic 
behaviors; however, male mice did not exhibit changes in the same parameters. 
Chen et al. (2006) created mice with a knock-in of the human Val66Met SNP of the BDNF gene. 
Similar to observations in humans, both hetero- (+/Met) and homozygous (Met/Met) Met-mice 
exhibited decreased total hippocampal volume and impaired contextual memory (Chen et al., 2006). 
However,  their  cue  memory  and  locomotor  activity  were  similar  to  the  control  animals.  Met/Met  
mice had increased weight, aggressiveness and anxiety-like behavior. In addition, the effects of 
fluoxetine were blocked in OF and NSF tests. Since their establishment, these mice have been used in 
several experiments. Both +/Met and Met/Met mice have impairment of their olfactory system (Bath 
et al., 2008). Met/Met mice exhibit anxiogenic behavior that is rescuable with music exposure (Li et 
al., 2010b), and +/Met exhibit vulnerability to stress-induced anxiety- and depression-like behavior 
(Yu et al., 2012). This stress-induced depression-like behavior in the +/Met mice can be rescued with 
desipramine but not fluoxetine (Yu et al., 2012).  
Direct infusion of BDNF to the DG of the HC causes antidepressant-like effects in rats 
(Shirayama  et  al.,  2002).  Thus,  increasing  BDNF  expression  in  the  brain  genetically  may  lead  to  
antidepressant-like behavior. Govindarajan et al. (2006) used mice overexpressing BDNF in excitatory 
neurons of the forebrain, including the hippocampus, cortex and amygdala, to test this hypothesis 
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(Huang et al., 1999). They observed an interesting behavioral phenotype of increased anxiety- and 
antidepressant-like behavior (Govindarajan et al., 2006). Furthermore, anxiogenic-like behavior was 
not caused by chronic immobilization stress. In contrast, another group found that these mice have 
anxiety-like behavior in the LD but not in the EPM (Papaleo et al., 2011). These authors did not 
observe changes in motor functions, contextual or cue fear memory or social or depression-like 
behavior. However, there were impairments in the working memory and auditory systems of these 
mice. The discrepancies between the results of these two independent experiments are likely 
attributable to sex differences because Govindarajan et al. used male mice and Papaleo et al. used 
female mice. Moreover, other studies have also demonstrated sex differences in genetically modified 
BDNF mice (Autry et al., 2009; Monteggia et al., 2007). Another line of mice overexpressing BDNF in 
the brain and other tissues exhibited enhanced performance in learning and memory tasks (Nakajo 
et al., 2008).  
Studies of mice with altered BDNF expression have been unable to establish a clear connection 
between depression and BDNF; some of the studies have yielded controversial results or no 
behavioral changes. Although BDNF protein levels are reduced by half in BDNF(+/-) mice throughout 
their lifespan, their behavioral phenotype is mild and varies among studies. This finding may be 
explained by developmental compensatory mechanisms, variations in genetic background (Jacobson 
& Cryan, 2007), differences in sex (Dalla et al., 2010) or differences in practices among laboratories 
(Wahlsten et al., 2003). Furthermore, conditional KOs and mice overexpressing BDNF are subject to 
the same problems as BDNF(+/-) mice; behavioral results vary widely depending on the laboratory and 
location and time period of transgene expression. Thus, there is growing interest in ligand-
independent genetic models of BDNF-TrkB-signaling (Table 6). 
TrkB-KO mice suffer from serious developmental problems and die during the first three 
postnatal weeks (Klein et al., 1993). Therefore, conditional TrkB-KO mice are essential to examine the 
behavioral effects of TrkB receptor-deficient mice. Mice with forebrain-specific TrkB-KO (TrkBCAMKII-CRE)
are viable, have normal brain morphology, and lack TrkB receptors in the HC and forebrain neocortex 
(Minichiello et al., 1999). These mice have a hyperactive phenotype with impulsive behavior and 
increased mobility in the FST (Zörner et al., 2003). However, these animals do not appear to exhibit 
changes in the test for anxiety-like behavior. Another mouse line in which TrkB was deleted in adult 
progenitors exhibited decreased locomotor activity and increased anxiety-like behavior (Bergami et 
al., 2008). In contrast, TrkB.TK+ mice with enhanced TrkB signaling (overexpression of the full-length 
catalytic form of the TrkB receptor) have been shown to have reduced anxiety- and depression-like 
behavior and improved contextual and associative learning and memory without changes in 
locomotor activity or coordination (Koponen et al., 2004; Koponen et al., 2005). In contrast, 
transgenic mice (TrkB.T1) with decreased TrkB signaling (overexpression of the truncated dominant 
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negative form of the TrkB receptor) displayed inhibition of the antidepressant-like effect of 
imipramine in behavioral despair models (Saarelainen et al. 2003).
Furthermore, Chen et al. (2005) produced another knock-in mouse line with a point mutation 
in the TrkB receptor (TrkBF616A). This mutation is not expected to influence the activity of the receptor, 
but when given a pharmacologically inert kinase inhibitor (1NMPP1), the activity of the TrkB receptor 
is inhibited. An advantage of these mice is that TrkB activity can be specifically and rapidly blocked 
without directly influencing the expression of TrkB. TrkBF616A mice have not yet been studied in large-
scale behavioral studies.  
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3 Aims of the study 
The purpose of these studies was to achieve a better understanding of the phenomena related 
to depression and AD action and to identify new methods for depression/antidepressant research. In 
more detail, the objective was to study the behavioral effects of genetic and pharmacological 
modification of BDNF-TrkB-signaling in mice. The specific aims of this thesis were as follows:  
I. To characterize the anxiety- and depression-like behavioral phenotype of TrkB-signaling 
deficient mice (TrkB.T1) and to compare the phenotype to that of heterozygous BDNF KO 
mice to better elucidate the importance of TrkB signaling in depression-related behavior. 
II. To  examine  the  effects  of  glutamatergic  drugs,  ketamine  and  the  AMPA  potentiator  LY  
451646  in  animal  models  of  behavioral  despair  and  the  role  of  BDNF  signaling  in  their  
mechanism of action. 
III. To investigate the influence of postnatal fluoxetine exposure and the potential rescuing 
effect  of  chronic  fluoxetine treatment  on the behavior  of  adult  mice to  examine the time-
dependent dualistic characteristics of ADs. 
IV. To study the role of fluoxetine-induced plasticity and BDNF in fear extinction in adult mice. 
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4 Experimental procedures 
4.1 Animals 
Mice were group-housed and maintained under a 12-h light–dark cycle (lights on from 6:00 am 
to 6:00 pm or 7:00 am to 7:00 pm), with food and water available ad libitum. Each group contained 
6-20 mice for behavioral testing and 4-11 mice for biochemical analysis. Mice used for fear 
conditioning were housed individually for 7 days prior to fear conditioning.  
All animal experiments were conducted in accordance with the Council of Europe (Directive 
86/609), the National Institute of Health Guidelines for the Care and Use of Laboratory Animals and 
Finnish guidelines. Efforts were made to minimize animal suffering and to use only the number of 
animals necessary to produce reliable scientific data. The State Provincial Office of Southern or 
Eastern Finland approved the experimental protocols.  
4.1.1 Animal genotypes 
Adult C57Bl/6J WT mice were obtained from the Laboratory Animal Center of the University of 
Helsinki or purchased from Harlan (Venrey, The Netherlands). 
Male B6.129S4-Bdnftm1Jae/J heterozygote mice (backcrossed to the C57Bl/6J background for 
more than 10 generations) (Ernfors et al., 1994) were obtained from Jackson Laboratory (Bar Harbor, 
ME,  USA;  Stock Number:  002266)  and bred with C57Bl/6J  female mice (Jackson Laboratory).  BDNF 
mRNA and protein expression is reduced by half in these animals during their development and 
adulthood. To eliminate BDNF gene expression, a part of exon 5 of the BDNF gene was deleted and 
replaced by a neomycin cassette for ablation. Because homozygous BDNF KO mice die during their 
first week of life, heterozygous mice and their WT littermates were used for testing.  
Generation of TrkB.T1 mice has been described previously by Saarelainen et al. (2000). These 
animals overexpress a truncated, dominant negative form of the TrkB receptor (TrkB.T1), which leads 
to decreased TrkB signaling activity. Because the transgene (N-terminally flag-tagged TrkB.T1 cDNA) 
was constructed under the Thy1 promoter, the TrkB.T1 receptor is expressed in postnatal neurons 
starting  from  postnatal  week  1.  Mice  were  originally  bred  and  maintained  in  the  CD2  (BALB/c  x  
DBA/2) background but were backcrossed to the C57BL/6J background for more than 10 generations. 
WT C57BL/6J females for breeding were purchased from Harlan (Venrey, The Netherlands). 
Heterozygous mice and their WT littermates were used for testing. 
The generation of the TrkBF616A mice has  been described earlier  by  Chen et  al.  (2005).  These 
mice carry  a  single  amino acid  mutation near  the ATP binding site  of  the receptor  that  makes the 
receptor susceptible to inhibition by a mutation-specific kinase inhibitor (1NMPP1). This mutation 
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and the use of 1NMPP1 allows for time-controlled inhibition of the TrkB receptor in this mouse. Mice 
were originally bred and maintained in the C57BL/6J background and maintained as an inbred strain, 
and homozygous females were bred with homozygous males. WT mice of the same origin were bred 
as a separate line and used as control animals for testing. 
4.2 Drug treatments 
4.2.1 Imipramine, ketamine and LY 451646 treatments 
Animals received a single intraperitoneal injection of a vehicle (0.5% 
hydroxypropylmethylcellulose and 1% Tween80 in water), ketamine (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany; 50 mg/kg), LY 451646 (N-[(2R)-2-(4'-Cyano[1,1'-biphenyl]-4-yl)propyl]-2-
propanesulfonamide; Eli Lilly Greenfield Labs, Greenfield, IN, USA; 5 mg/kg) or imipramine (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany; 30 mg/kg) in a volume of 10 ml/kg and  were subjected 
to behavioral analysis either 35-45 min or 7 days after the injection. Doses were selected based on 
preliminary studies and the literature (Popik et al 2008; Bai et al 2001).  
4.2.2 Fluoxetine treatments 
Mice received fluoxetine (kindly provided by Dr. Jukka Sallinen, Orion Pharma, Helsinki, Finland) 
via drinking water in light-protected tubes. Solutions were prepared fresh daily. Fluoxetine was 
dissolved  in  tap  water  at  a  concentration  of  0.08  mg/ml  (approximately  10  mg/kg/day).  The  
treatment continued through all behavioral sessions until sacrifice. 
For postnatal fluoxetine administration (PNF), litters were randomly assigned to two groups: 
saline-injected (SAL, n=18 male pups) and fluoxetine-injected (FLX, n=24 male pups). Pups from each 
group were weighed and injected intraperitoneally daily (10:00 am–11:00 am) with either saline 
[1 ×  phosphate-buffered saline (PBS), 5 ml/kg] or fluoxetine (dissolved in 1 × PBS, 10 mg/kg, 5 ml/kg) 
starting at postnatal day 4 (P4) until P21 (Ansorge et al., 2004).  
4.2.3 1NMPP1 kinase inhibitor 
The TrkBF616A mice and their control animals were treated with the kinase inhibitor 1NMPP1 [1-
(1,1-Dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; kindly provided 
by Professor Jari Yli-Kauhaluoma and Kirsi Harju, Division of Pharmaceutical Chemistry, Faculty of 
Pharmacy, University of Helsinki, Helsinki, Finland] in their drinking water one week prior and during 
the behavioral testing (Bishop et al., 1999; Sallert et al., 2009). The concentration of 1NMPP1 in the 
drinking water was 5.0 μM. 
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4.3 Behavioral testing 
The behavioral experiments were conducted in the order presented below, and the interval 
between subsequent tests was 2–3 days during the light phase. The experimenter was blind to the 
animal genotype and/or treatment. At the beginning of behavioral testing, the animals were 2–3 
months (young adult) or 12 months (middle-aged) old.  
4.3.1 Exploratory activity/Open field (I, II, III) 
The spontaneous exploratory activity of mice was automatically monitored in a transparent, 
well-illuminated (~ 300 lx) cage equipped with two stacked frames of infrared photo detectors 
enabling separate monitoring of horizontal (XY-move time) and vertical activity (rearing). The young 
adult mice were tested using an activity monitor produced by MED Associates (cage dimensions, 28.5 
cm × 28.5 cm x 20 cm; St. Albans, VT, USA), while middle-aged mice were tested with the TruScan® 
activity monitor (cage dimensions, 26 cm x 26 cm x 39 cm; Coulbourn Instruments, CO, USA). The test 
sessions for young adult mice were 30 min, while the sessions for middle-aged mice were 10 min. To 
avoid odor traces, the test cage was cleaned with 70% ethanol before each mouse. 
For analysis of results, the cages were divided into two compartments: a compartment near 
the walls (7 cm from the walls) and a central area compartment. Interruptions of infrared photo 
beams were used to calculate the following parameters: the distance traveled (cm), time spent in 
compartments, immobility time and rearing.  
4.3.2 Light/dark-box test (III) 
The LD test was performed for 10 min in an acrylic cage (28.5 × 28.5 × 20 cm; MED Associates, 
St. Albans, VT, USA) divided into two equal size compartments: one with transparent walls that was 
open topped and brightly illuminated (~ 450 lx from a 40-W light bulb fixed 55 cm above the floor) 
and another compartment that was constructed from black plastic (passing infrared light) and 
covered by a lid. The two compartments were separated by a partition containing an opening 
(7 × 5 cm) in its center at floor level. The mouse was placed in the center of the light compartment 
facing  away  from  the  opening.  The  latency  to  enter  the  dark  area,  the  time  spent  in  the  
compartments, the total distance traveled, the immobility time and the number of entries into the 
dark  compartment  were  measured  over  10  min.  Rearing  time  was  also  calculated.  The  testing  
apparatus was thoroughly cleaned after each animal using 70% ethanol.
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4.3.3 Elevated Plus-maze test (I, III) 
This test was performed in an elevated maze (40 cm above the floor) consisting of two open 
arms (30 cm x 5 cm), two enclosed arms (30 cm x 5 cm with 15-cm-high transparent or black-painted 
side and end walls) and a connecting central platform (5 cm x 5 cm). The mouse was placed on the 
central platform facing one of the enclosed arms, and the time spent in the open and closed arms 
and the number of total arm entries was observed for 5 minutes. A video camera positioned above 
the maze recorded the experiments (Ethovision XT 7, Noldus Information Technology, Wageningen, 
Netherlands). The total number of arm visits was taken as a measure of general activity, while the % 
time spent in the open arms was used as a measure of anxiety. Only mice with at least 5 arm entries 
were considered when calculating the latter parameter. Testing occurred in a dimly lit room. To avoid 
odor traces, the test cage was cleaned with 70% ethanol before each mouse. 
4.3.4 Forced swimming test (I, II, III) 
Mice were placed individually in glass cylinders (19 cm in diameter, 24 cm high) filled with 
water at 21 ± 1 °C to a height of 14 cm. If used, the test compounds and vehicle were administered 
45 minutes prior to testing. The time spent immobile (passive floating, during which the animal was 
motionless or moving the tail or one hind limb only slightly) was measured during the 6 min test. The 
latency  to  the  first  bout  of  immobility  was  also  recorded.  The  results  were  normalized  to  the  
respective controls and expressed as a percentage of the control.  
4.3.5 Novel object recognition (I) 
A pair of identical objects was left overnight in the home cage and removed the next morning. 
After 4 hours, a new pair of objects, one identical to the previous pair and a novel object, was placed 
side by side at the back of the cage (the side of the novel object was randomized between days). The 
behavior of the animal was monitored for 5 minutes, and the approaches to the objects were 
counted. Four pairs of objects were used [three of them were DuploR toy building blocks (Lego, 
Denmark)] that were similar in size to the mouse; the last pair of objects was a drinking glass and a 
metal tea jar (height ~ 9 cm). The total number of approaches to the objects and novelty preference 
was counted over the four days. The formula for novelty preference was as follows: 
[(visits to novel – visits to familial)/total visits] * 100% 
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4.3.6 Marble Burying (I) 
The test was conducted in the home cage (27 cm x 45 x cm 14.5 cm). In the afternoon, 1 l of 
extra bedding was added to the cage bottom, and 9 glass marbles (1 cm in diameter) were left on the 
top of the new bedding in a 3 x 3 array. The next morning, the number of uncovered marbles was 
counted.
4.3.7 Fear conditioning, extinction, renewal and reinstatement (IV) 
Freezing behavior was measured with an automatic infrared beam detection system, which 
was placed on the sides of the chamber of the fear conditioning apparatus (TSE Systems GmbH, Bad 
Homburg, Germany). The mouse was considered to be frozen only if it was not moving for at least 3 s, 
and the measurement was expressed as the percentage of the time spent freezing. Fear conditioning 
and extinction occurred in two different contexts unless otherwise stated. Fear conditioning context 
(A) was a transparent Plexiglas chamber with metal grids on the floor, whereas extinction context (B) 
was a black nontransparent Plexiglas chamber with a planar floor. Both context A and context B were 
cleaned before each session with 70% ethanol or 70% 2-propanol, respectively. 
Fear conditioning. During the fear conditioning, the mice were conditioned with 5 pairings of 
the CS (total CS duration 30 s, 1 Hz, white noise, 80 dB) with the US (1 s foot shock of 0.6 mA, inter-
trial interval: 20-120 s). The US co-terminated with the CS. The freezing level during the first CS, 
preceding the first US, was taken as the baseline freezing during CS.  
Fear extinction.  After  fear  conditioning  (Days  2  and  3),  mice  were  submitted  to  extinction  
training in context B. During this training, the mice received 12 presentations of the CS on each day 
(inter-trial interval: 20-60 s). Spontaneous recovery and context-dependent fear renewal were tested 
7 days later in context B and context A, respectively, using 4 presentations of the CS (inter-trial 
interval: 20-60 s). 
Fear renewal. After fear conditioning, the mice were assigned to 2 groups with equal levels of 
freezing: one received fluoxetine in the drinking water until the end of the experiment, while the 
other received tap water. On days 14 and 15, the conditioned mice were submitted to extinction 
training in context B, during which they received 12 daily presentations of the CS (inter-trial interval: 
20-60 s). Spontaneous recovery and context-dependent fear renewal were tested 7 days later in 
context B and context A, respectively, using 4 presentations of the CS (inter-trial interval: 20-60 s). 
Fear reinstatement.  All  experimental  procedures  were  conducted  in  context  A.  After  fear  
conditioning, mice were assigned to 2 groups with equal levels of freezing: one received fluoxetine in 
the drinking water until the end of the experiment, while the other received tap water. On days 14 
and 15, the conditioned mice were submitted to extinction training, during which they received 12 
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daily  presentations  of  the  CS  (inter-trial  interval:  20-60  s).  7  days  later,  the  mice  received  5  
unsignaled US; 24 hours later, fear reinstatement was tested using 4 presentations of the CS (inter-
trial interval: 20-60 s). To control for the context specificity of the fear reinstatement test, mice were 
additionally tested in the new context B 2 hours later using 4 presentations of the CS (inter-trial 
interval: 20-60 s), during which the mice did not exhibit elevated freezing behavior. 
4.4 Biochemical analysis (II) 
4.4.1 Preparation of biological samples 
Animals were stunned with CO2 and killed by rapid decapitation, and hippocampi were rapidly 
dissected on a cooled dish. Samples were stored at - 80 °C until use. Frozen tissue was homogenized 
in cooled NP++ lysis buffer [137 mM NaCl; 20 mM Tris, pH 8.0; 1% NP-40; 10% glycerol, 50 mM NaF, 
2× Complete Mini (Roche Diagnostics, Hertforshire, UK) and 2 mM Na3VO4], proteins were extracted, 
and Trk receptor phosphorylation was measured as previously described (Aloyz et al., 1999; 
Rantamäki et al., 2007; Saarelainen et al., 2003). 
4.4.2  Western blotting 
All glycosylated proteins, including Trk receptors, were precipitated using lectin beads (wheat 
germ  agglutinin;  EY  Laboratories,  San  Mateo,  CA,  USA).  Next,  the  beads  were  washed  extensively  
with NP++ buffer, and specifically bound proteins eluted upon heating in Laemmli sample buffer. 
Samples were separated by SDS-PAGE and blotted on a PVDF membrane for pTrk immunoblot 
detection (anti-pY705/6; 1:1000; Cell Signaling Technology, Danvers, MA, USA). The efficiency of 
lectin precipitation was confirmed by Ponceau staining. Trk receptor phosphorylation levels were 
normalized to total Trk-receptor levels with the SC-11 (1:2000, Santa Cruz Biotechnology, Dallas, 
Texas, USA) antibody as previously described (Aloyz et al., 1999; Rantamäki et al., 2007; Saarelainen 
et al., 2003). 
4.4.3 ELISA
BDNF protein levels were analyzed using a BDNF ELISA (enzyme-linked immunosorbent assay) 
according to Karpova et al. (2010). The results are shown as the percentage of the respective controls. 
4.5 Statistical analysis 
Data obtained from behavioral tests were analyzed with STATVIEW software (SAS, Cary, NC, 
USA) or with SPSS for Windows 14.0 software. For comparisons between 2 groups, an unpaired, two-
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tailed Student’s t-test was performed for parametric data, and the Mann-Whitney U-test was used 
for non-parametric data. Two-way ANOVA was used to reveal the main effect and interaction 
between the factors, followed by Fisher’s PLSD test. For the fear conditioning test, statistical analyses 
were performed using repeated-measures ANOVA followed by Student’s paired or unpaired two-
tailed t-test.  The  criterion  for  significance  was  P<0.05.  All  values  reported  in  the  text,  table  and  
figures represent the mean ± SEM. 
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5 Results  
5.1 Behavioral phenotyping of TrkB-signaling deficient mice (I)
To examine the influence of decreased TrkB signaling on depression- and anxiety-like behavior, 
we tested mice overexpressing a dominant negative form of the TrkB receptor (TrkB.T1). Both male 
and female mice were tested in two cohorts of mice: young adult and middle aged. In addition, to 
compare BDNF-ligand-dependent and –independent transgenic models, heterozygous BDNF KO mice 
were tested to identify differences in comparison with TrkB.T1 mice. 
5.1.1 TrkB.T1 mice show lack of motivation and indifference to surrounding environment 
The spontaneous activity and exploration behavior of TrkB-signaling-deficient mice (TrkB.T1) 
were examined in a novel empty cage. Young adult TrkB.T1 mice displayed a non-significant toward a 
decrease  in  total  distance  traveled  (two-way  ANOVA,  P=0.091)  (I,  Figure  1.A).  However,  this  trend  
became significant in aged mice (two-way ANOVA, P=0.004) and was particularly apparent in female 
mice  (I, Figure 1.B). In rearing behavior, young adult male TrkB.T1 mice exhibited a decreased 
number of rearings (P=0.014) compared to female mice, who were indistinguishable from their 
littermate controls (I, Figure 1.C).  
The  anxiety–related  behavior  of  TrkB.T1  mice  was  tested  in  the  EPM  test.  Both  young  adult  
and middle-aged TrkB.T1 mice were indistinguishable from their littermate controls when total arm 
entries were measured, indicating that the TrkB.T1 mice explored the maze similarly to WT mice (I,
Figure 2.C-D). Both young adult (P=0.032) and middle-aged male (two-way ANOVA, genotype: 
P=0.017)  TrkB.T1 mice displayed a  significant  increase in  the time spent  in  open arms,  more likely  
indicating anxiolytic-like than anxiogenic-like behavior (I, Figure 2.A-B).  
To measure object xenophobia, middle-aged TrkB.T1 mice were subjected to the MB and NOR 
tests. In the MB test, TrkB.T1 mice buried an equal amount of marbles compared to the controls (I,
Figure 3.A). However, in the NOR test, TrkB.T1 mice showed less interest (approaches) to the novel 
objects (two-way ANOVA, P<0.001). Because both male and female mice made fewer approaches to 
the familiar objects, their preference for the novel objects was indistinguishable from their controls 
(P=0.25) (I, Figure 3.B-C). 
The depression-like behavior of young adult TrkB.T1 mice was characterized in the FST. Two-
way ANOVA revealed significant differences between genotypes (P=0.004), sexes (P=0.027) and a 
genotype  x  sex  interaction  (P=0.009)  in  total  immobility  time  (I,  Figure  4.A).  Similarly,  there  were  
significant differences in the latency to the first immobility between genotype x sex interaction 
(P=0.012) but not between genotype or sex alone (I, Figure 4.B). Thus, male TrkB.T1 mice exhibited 
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increased immobility time (P<0.001) and decreased latency to immobility (P=0.004) compared to WT 
littermate controls, while female mice displayed no changes in their behavior. 
5.1.2  Behavioral phenotype of BDNF(+/-) animals
The spontaneous activity and exploration behavior of the heterozygous BDNF KO mice 
(BDNF(+/-)) were examined in a novel empty cage. Both young adult and middle-aged BDNF(+/-) mice 
were indistinguishable from their littermate controls in exploratory behavior (I, Figure 5.A-D). 
However, middle-aged female mice traveled longer during test time compared to the middle-aged 
male mice (P=0.028).  
The anxiety–related behavior of the middle-aged BDNF(+/-) mice  was  tested  in  the  EPM  test.  
When compared to their control groups, both male and female BDNF(+/-) mice displayed a similar 
level  of  arm entries  (I,  Figure 6.B).  However,  both sexes  spent  more time in  the open arms of  the 
EPM (two-way ANOVA, P=0.001) (I, Figure 6.A).  
To measure object xenophobia, middle-aged BDNF(+/-) mice were subjected to the MB and NOR 
tests. In the MB test, BDNF(+/-) animals displayed the genotype X sex interaction (P=0.003); male 
TrkB.T1 mice buried more marbles than their controls, while female mice and their controls buried 
equal numbers of marbles (I,  Figure  7.A).  In  the  NOR  test,  no  genotype  effect  was  evident,  but  a  
significant difference between sexes was observed, as female mice made a greater number of 
approaches  to  the  novel  objects  compared  to  male  mice  (P<0.001)  (I,  Figure  7.B-C).  However,  a  
significant difference between genotypes in novelty preference was observed in both sexes (P=0.034). 
The depression-like behavior of young adult male BDNF(+/-) mice was measured in the FST. No 
significant  differences  were  observed  in  the  immobility  time  or  the  latency  to  immobility  of  these  
mice (I, Figure 8.A-B). 
5.2 Behavioral phenotyping of the TrkBF616A mice 
The TrkBF616A mice were tested in the behavioral test battery. 4 groups were formed with two 
genotypes (WT or TrkBF616A)  and  two  treatments  (water  or  1NMPP1)  (Table  7).  Contrary  to  our  
expectations, in the absence of an inhibitor, the TrkBF616A mice exhibited significant differences in the 
LD and EPM tests and trends in the FST (Table 7). The mice also exhibited differences in baseline 
freezing and altered contextual memory in the FC test (data not shown). Furthermore, the 1NMPP1 
inhibitor appeared to influence the behavior of the WT mice but did not alter the behavior of the 
TrkBF616A mice. 
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Table  7.  The  behavior  of  the  TrkBF616A mice. All data are presented as group the mean±SEM. Data 
were  analyzed  by  two-way  ANOVA  followed  by  Fischer’s  post  hoc  –test.  *  P<0.05,  **  P<0.01,  ***  
P<0.001 vs. WT/Control group; # P<0.05, ## P<0.01 vs. TrkBF616A/Control group. 
WT TrkBF616A
Control 1NMPP1 Control 1NMPP1 
Number of animals: 6 8 8 6 P-value 
L/D: 
Zone entries to light (no) 32.2±4.9 24.6±1.6** 16.8±2.9*** 22.6±0.9** 
GT 0.010; GT vs. TREAT
0.039 
Time in light (s) 197.2±41.5 128.9±15.2## 323.3±65.1 174.7±39.2# TREAT 0.037 
Total resting time (s) 383.9±7.6 400.6±12.0 433.1±22.8 404.1±10.7 n.s. 
OF:
Distance traveled (cm) 2082±107 2059±272 1741±264 2114±279 n.s. 
EPM: 
Time in open arms (%) 14.6±6.1 1.5±0.9* 1,6±0.9* 8.7±5.8 GT vs. TREAT 0.018 
Total arm entries (no) 15.2±1.4 9.6±0.7* 11.4±1.0* 10.0±1.6* TREAT 0.008 
FST:
Immobility time (s) 155.8±14.0 83.5±28.2 101.62±32.0 46.4.±18.1* TREAT 0.025 
Latency to immobility (s) 72.5±9.7 160.0±38.5 171.9±32.8 171.9±31.4 n.s. 
5.3 The behavioral effects of glutamatergic drugs in WT and BDNF(+/-) mice (II)
To investigate the acute and long-lasting antidepressant-like effects of glutamatergic drugs, 
mice were treated with the NMDA receptor antagonist ketamine and the AMPA receptor potentiator 
LY 451646 45 min or 7 days prior to testing. BDNF(+/-) mice were used to examine the importance of 
BDNF signaling in the mechanism of action of these drugs. 
5.3.1 Ketamine induced an antidepressant-like effect in WT and BDNF(+/-) mice without 
changes in phosphorylated-Trk or BDNF protein levels 
Acute (45 min) ketamine administration (50 mg/kg) induced antidepressant-like effects in WT 
mice in  the FST.  Ketamine decreased total  immobility  time (P=0.011)  and increased latency to  the 
first appearance of immobility (P=0.016) (Table 8). This antidepressant-like effect disappeared at 7 
days after ketamine administration. However, ketamine did not influence the total distance traveled 
or time spent in the open area in the OF test.  
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Table  8.  Behavioral  effects  of  ketamine  (50  mg/kg)  in  WT  mice  in  the  FST  and  OF.  FST  data  are  
presented as the percentage of the control as the group mean±SEM and OF data as the group 
mean±SEM. Data were analyzed from the original values by an unpaired t-test. * P<0.05.   
Control N Ketamine N P-value
FST: After 45 min Latency (%) 100±10.3 8 208.5±38.3* 8 0.016
Immobility (%) 100±12.3 8 32±19.1* 8 0.011
FST: After 7 days Latency (%) 100±24.0 9 94±20.8 10 n.s.
Immobility (%) 100±16.5 9 93±16.4 10 n.s.
OF: After 35 min Time spent in center (s) 272.8±44.4 8 280.4±83.0 6 n.s.
Distance traveled (cm) 3672±395 8 4492±751 7 n.s.
Furthermore, ketamine did not induce any changes in phosphorylated-Trk or BDNF protein 
levels, either acutely or 7 days after the ketamine injections (Table 9).  
Table 9. Influence of ketamine (50 mg/kg) on BDNF protein and pTrk levels in the HC of WT mice. All 
data are presented as the percentage of the control as the group mean±SEM. Data were analyzed by 
an unpaired t-test. * P<0.05.   
Control N Ketamine N P-value
Acute: after 60 min pTrk/Trk 100±10.1 9 132.7±18.3 10 n.s.
BDNF prot. 100±4.1 4 98.4±1.6 5 n.s.
After 7 days pTrk/Trk 100±10.7 11 143.1±23.6 11 n.s.
BDNF prot. 100±3.2 9 96.1±4.9 10 n.s.
In BDNF(+/-) mice, acute ketamine administration caused antidepressant-like effects in the FST 
by  decreasing  the  total  immobility  time  (two-way  ANOVA,  genotype  x  treatment  P=0.0069;  
WT/control vs. WT/ketamine P=0.0169; WT/control vs. BDNF(+/-)/ketamine P=0.0022; BDNF(+/-)/
control vs. BDNF(+/-)/ketamine P=0.0022) (Figure 3). Meanwhile, the effect of the tricyclic AD 
imipramine was lost in these mice.  
Furthermore, ketamine did not induce any changes in BDNF protein levels acutely or at 7 days 
after injections (Figure 4). However, as described in the literature (Rantamäki et al., 2013), total 
BDNF protein levels were decreased by approximately 40% in BDNF(+/-) mice when compared to their 
WT littermates (P<0.0001). 
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Figure 3. Acute (after 45 min) behavioral effects of ketamine (50 mg/kg) and imipramine (30 mg/kg) 
in BDNF(+/-)mice  in  the  FST.  All  data  are  presented  as  a  percentage  of  the  control  as  the  group  
mean±SEM. Data were analyzed from original values by two-way ANOVA followed by Fischer’s post 
hoc–test. * P<0.05, ** P<0.01 vs. WT/Control group; # P<0.05 vs. BDNF(+/-)/Control. 
Figure 4. BDNF protein levels acutely (after 60 min) and 7 days after a single ketamine injection (50 
mg/kg) in WT and BDNF(+/-) mice. All data are presented as the percentage of the control as the group 
mean±SEM. Data were analyzed by two-way ANOVA followed by Fischer’s post hoc–test. *** P<0.001 
vs. WT/Control group; ### P<0.001 vs. BDNF(+/-)/Control. 
5.3.2  An AMPA potentiator induced antidepressant-like effects in WT and BDNF(+/-) mice
without changes in phosphorylated-Trk or BDNF protein levels 
Acute (45 min) LY 451646 administration (5 mg/kg) induced antidepressant-like effects in WT 
mice in the FST. LY 451646 decreased total immobility time (P=0.0001) and increased latency to the 
first appearance of immobility (P=0.043) (Table 10). However, LY 451646 did not influence the total 
distance traveled or the time spent in the center area in the OF test. Furthermore, no changes in 
phosphorylated-Trk  or  BDNF  protein  levels  were  observed  acutely  or  at  7  days  after  LY  451646  
injection (Table 11).   
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Table 10. Behavioral effects of LY 451646 (5 mg/kg) as observed in the FST and OF with WT mice. FST 
data are presented as the percentage of the control as the group mean±SEM and OF data as the 
group mean±SEM. Data were analyzed from original values with an unpaired t-test. * P<0.05, *** 
P<0.001. 
Control N LY 451646 N P-value
FST: after 45 min Latency (%) 100±30.7 8 211.8±39.9* 8 0.043
Immobility (%) 100±15.9 8 8.1±5.9*** 8 0.0001
OF: after 35 min Time spent in center (s) 272.8±44.4 8 277.4±58.3 8 n.s.
Distance traveled (cm) 3672±395 8 3496±360 8 n.s.
Table 11. Influence of LY 451646 (5 mg/kg) on BDNF protein and pTrk levels in the HC of WT mice. All 
data are presented as the percentage of the control as the group mean±SEM. Data were analyzed 
with an unpaired t-test. 
Control N LY 451646 N P-value
Acute: after 60 min pTrk/Trk 100±7.2 4 95.4±1.1 4 n.s.
BDNF prot. 100±10.0 4 87.8±2.1 4 n.s.
After 7 days pTrk/Trk 100±7.2 4 103.2±6.9 4 n.s.
BDNF prot. 100±10.0 4 88.7±3.1 4 n.s.
In BDNF(+/-) mice, acute LY 451646 administration caused an antidepressant-like effect in the 
FST by decreasing the total immobility time (two-way ANOVA: treatment, P=0.0001; WT/control vs. 
WT/LY 451646, P<0.001; WT/control vs. BDNF(+/-)/LY 451646, P<0.001; BDNF(+/-)/control vs. BDNF(+/-) 
/LY 451646, P=0.003) (Figure 5). 
Figure 5. Acute (after 45 min) behavioral effects of LY 451646 (5 mg/kg) in BDNF(+/-)mice in the FST. 
All data are presented as the percentage of the control as the group mean±SEM. Data were analyzed 
from original values by two-way ANOVA followed by Fischer’s post hoc test. ** P<0.01, *** P<0.001 
vs. WT/Control group; ## P<0.01 vs. BDNF(+/-)/Control. 
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5.4 Potential behavioral alterations induced by early postnatal fluoxetine treatment (III)
To examine the long-term behavioral effects of early exposure of mice to ADs, male C57Bl/6J 
mice  were  treated  during  postnatal  days  P4-P21  with  daily  injections  of  saline  or  fluoxetine  (10  
mg/kg). Furthermore, to measure the potential rescuing effect of adult AD treatment, starting from 
day P90, these two groups were randomly divided further into two groups: mice drinking regular 
water and mice receiving fluoxetine in the drinking water (0.08 mg/ml). Treatments started 21 days 
prior to behavioral testing and lasted until sacrifice. The experimental groups are shown in Figure 6. 
The depression- and anxiety-like phenotypes of these mice were tested using a behavioral test 
battery. 
Figure 6. Experimental groups in the early fluoxetine exposure study. 
5.4.1 Postnatal fluoxetine treatment decreases body weight and explorative activity 
Postnatal fluoxetine treatment significantly decreased the body weight of mice (t=3.714, 
DF=40, P<0.001), and this decrease was observed throughout the entire lifespan of the mice (P90, 
P=0.006) (Figure 7). Later in life, fluoxetine treatment rescued this weight loss to the control level. 
However, adult fluoxetine treatment did not have any effect on the weight of the mice who received 
saline injections in early life (two-way ANOVA: ADF, P<0.0001; PNF x ADF interaction, P<0.05).  
In the OF test, PNF treatment slightly decreased the distance mice traveled during 30 minutes 
(two-way ANOVA: P<0.05) (III, Table 1). However, no differences in the ADF or PNF x ADF interaction 
were identified. According to Fisher’s (PLSD) post hoc test, no statistically significant difference was 
identified. Moreover, PNF treatment significantly decreased (two-way ANOVA, P<0.0001) and ADF 
increased (two-way ANOVA, P<0.001) the total rearing time. Post hoc analysis revealed that the total 
rearing time was decreased in the FW group compared to the controls. 
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Figure  7.  Effect  of  postnatal  (10  mg/kg,  daily  P4-P21)  and  adult  (0.08  mg/ml  via drinking water, 
starting from P90) fluoxetine treatments on the weight of mice. All data are presented as the group 
mean±SEM. Data were analyzed by unpaired t-test or two-way ANOVA followed by Fischer’s post hoc
test. * P<0.05, *** P<0.001. 
5.4.2 Postnatal fluoxetine treatment-induced anxiety-like behavior was rescued by adult 
fluoxetine treatment 
The effects of PNF and ADF treatments on anxiety-like behavior were measured using the OF 
and LD tests.  In  the OF test,  PNF-treated mice displayed increased total  immobility  time (two-way 
ANOVA, P<0.01), with a trend toward moving later to walls (two-way ANOVA, P=0.09) (III, Table 1). In 
the post hoc analysis (Fisher’s PLSD), the FW group showed a statistically significant increase in the 
total and central area immobility times (P<0.05); this phenotype was rescued by ADF treatment. 
However, the time in the central area, the distance traveled in the central area, the center-wall 
transition and the rearing time in the central area were not affected by the treatments. 
In the LD test, PNF treatment decreased the total distance traveled (two-way ANOVA, P<0.001) 
and total rearing time (two-way ANOVA, P<0.0001), while ADF increased the same parameters (two-
way ANOVA, P<0.05 and P<0.0001, respectively) (III,  Table  1).  In  addition,  PNF increased (two-way 
ANOVA,  P<0.001)  and  ADF  decreased  (two-way  ANOVA,  P<0.05)  total  immobility  time.  Moreover,  
PNF-treated mice showed a tendency toward increased latency to enter the dark compartment (two-
way ANOVA, P=0.012). However, the distance traveled in, the time spent in or the entries to the light 
compartment were not affected by the treatments. 
5.4.3 Effects on depression-like behavior 
The effects of the PNS and ADF treatments on depression-like behavior were measured in the 
FST. PNF-treated mice were less immobile compared to the ADF-treated mice (two-way ANOVA, 
P<0.001), while the latencies to immobility were longer and shorter for PNF and ADF, respectively 
(two-way ANOVA, P<0.05) (Figure 8). However, the post hoc analysis (Fischer’s PLSD) revealed no 
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statistically significant differences between groups in latencies to immobility, and differences in 
immobility time were observed only between the SW and FW groups (P<0.05). 
Figure  8.  Effect  of  postnatal  (10  mg/kg,  daily  P4-P21)  and  adult  (0.08  mg/ml  via drinking water, 
starting  from  P90)  fluoxetine  treatment  on  the  depression-like  behavior  of  mice.  All  data  are  
presented as the group mean±SEM. Data were analyzed with two-way ANOVA followed by Fischer’s 
post-hoc test. * P<0.05. 
5.5 Fluoxetine-induced re-opening of developmental-type plasticity in fear circuitry:  the 
role of TrkB (IV)
In this study, we investigated whether fluoxetine can open developmental-type plasticity and 
enable, in conjunction with an environmental stimulus, recovery of permanent fear extinction 
memory similar to what has been observed in the rat visual cortex. Four different study setups were 
performed.  All  mice were conditioned to  the CS (a  30 s  white  noise),  followed by the US (1  s  foot  
shock)  in  context  A.  After  fear  conditioning  (on  Days  2  and  3),  mice  were  submitted  to  extinction  
training in context B.  
Setup 1. Mice received water or fluoxetine (0.08 mg/ml via drinking water) for 3 weeks prior to 
and during the testing. Spontaneous recovery and context-dependent fear renewal were tested at 7 
days after extinction in context B and context A, respectively, using 4 presentations of the CS. After 
extinction control, mice displayed spontaneous recovery (P<0.05) and fear renewal (P<0.05), while 
the fear extinction in the fluoxetine-treated mice was permanent (IV,  Figure  1).  However,  both  
control and fluoxetine-treated mice without extinction displayed a similar fear response in the fear 
renewal test. Moreover, fluoxetine-treated mice with extinction showed significantly reduced 
freezing when compared with fluoxetine-treated mice without extinction (P<0.001), indicating the 
effectiveness of the extinction training. 
Setup  2.  After  fear  conditioning,  mice  were  assigned  to  two  groups  with  equal  levels  of  
freezing, one of which received fluoxetine in the drinking water until the end of the experiment, 
while  the  other  received  tap  water.  On  days  14  and  15,  the  conditioned  mice  were  submitted  to  
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extinction training in context B, during which they received 12 presentations of the CS each day. 
Spontaneous recovery and context-dependent fear renewal were tested 7 days later in context B and 
context A, respectively, using 4 presentations of the CS. Similar to Setup 1, control mice exhibited 
spontaneous recovery and fear renewal (P<0.05), while the fear extinction of fluoxetine-treated mice 
was permanent (IV, Figure 2.C). However, both control and fluoxetine-treated mice without 
extinction exhibited a similar fear response in the fear renewal test. Moreover, fluoxetine-treated 
mice with extinction displayed significantly reduced freezing when compared with fluoxetine-treated 
mice without extinction (P<0.05). 
Setup  3.  After  fear  conditioning,  mice  were  assigned  to  two  groups  with  equal  levels  of  
freezing, one of which received fluoxetine in the drinking water until the end of the experiment, 
while  the  other  received  tap  water.  On  days  14  and  15,  the  conditioned  mice  were  submitted  to  
extinction training, during which they received 12 presentations of the CS each day. Seven days later, 
the  mice  received  5  unsignaled  US;  24  hours  later,  fear  reinstatement  was  tested  using  4  
presentations of the CS. Although both groups displayed increased freezing (control, P<0.01; 
fluoxetine, P<0.01) compared to the results of the extinction training, the fluoxetine-treated group 
displayed significantly reduced freezing compared to the control mice (P<0.05) (IV, Figure 2.C). 
Setup 4. Control and fluoxetine-treated BNDF(+/-) mice and their littermate WT control mice 
were exposed to similar conditions as in Setup 1. While fluoxetine-treated WT mice exhibited 
permanent fear extinction, BNDF(+/-) mice exhibited a similar level of freezing when compared to the 
control animals (IV, Figure 4.B). 
Discussion
51
6 Discussion 
6.1 Challenges of measuring depression-like behavior in mice 
The discovery of antidepressants almost 60 years ago revolutionized the treatment of MDD. 
ADs were shown to increase serotonin and norepinephrine levels in the brain, which led to the 
formation of the monoamine theory of depression (Schildkraut, 1965). However, clinical findings and 
biochemical studies suggest that the pathology of depression is more complex and that monoamine 
deficiency alone cannot explain depression (Hindmarch, 2002). Furthermore, the unsatisfying 
interpretive ability of the monoamine theory and the identification of a connection between the 
neurotrophin BDNF and depression, particularly antidepressant effects, resulted in the formation of 
the neurotrophin hypothesis of depression. Increased support of this theory has led to countless 
studies evaluating the connection between BDNF and depression and the importance of BDNF in the 
mechanism of action of ADs (Adachi et al., 2008; Castrén et al., 2007; Duman & Monteggia, 2006). 
Broad variety and individuality in MDD patients and their symptoms makes modeling this 
complex disorder challenging. After the discovery of ADs a half century ago, several “depression 
models” were introduced. These models focused on a monoamine-based mechanism of action for 
ADs. Many potential new ADs may give false-negative results in these models. Behavioral despair 
models  of  depression (LH,  FST and TST)  give  positive  results  for  all  clinically  active  AD treatments,  
including ECT, but do they really model depression? The major drawback of despair models is that, in 
practice, they do not have construct validity as a depression model because ADs work acutely in 
these tests, whereas in clinical care, long-term treatments are needed (Willner & Mitchell, 2006). 
Several other behavioral depression models have been established. The most auspicious tests are 
related to chronic stress; CMS and OB both enhance biochemical changes that are similar to those 
observed in depressed patients (Papp et al., 1996; Shepherd, 2006). In addition, these models also 
mimic,  at  least  in  part,  symptoms  of  depression.  Moreover,  chronic  treatment  with  ADs  yields  
positive  results  in  these  models  (Roche  et  al.,  2007;  Strekalova  et  al.,  2006).  However,  how  can  
depression be diagnosed in a mouse or rat models, and do these animals actually experience 
depression? Thus, more precise tests are needed to model depressive symptoms. 
What constitutes a good mouse model of depression or depressive symptoms? A single test 
measuring the behavioral despair of a mouse is insufficient to model this complex disorder. However, 
combining several tests that measure different symptoms may be a better solution because 
evaluating different aspects of the symptomology of depression increases the face validity of a model. 
Furthermore, a good model of MDD should also have some predictive validity; several classes of ADs 
should give positive results in chronic use. Dzirasa and Covington (2012) have introduced criteria for 
mouse affective syndrome (MAS). This model includes several tests in three domains. The first 
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domain includes reward-related symptoms of MDD: anhedonia and decreased concentration. The 
first can be measured by an intracranial self-stimulation or sucrose preference test, and the second 
can be measured with a 5-hole nose poke test. The second domain (homeostatic factors) contains 
three symptomatic groups: psychomotor retardation or agitation, insomnia or hypersomnia and 
changes in appetite or weight, which can easily be measured by observing changes in dark-cycle 
locomotion, sleep patterns, food consumption and weight, respectively. As the third domain, Dzirasa 
and Covington (2012) listed changes in biochemical, molecular and neurophysiological markers, such 
as alterations in cortical gene expression or enhanced cortico-limbic network synchrony.  
6.2 Effects of the genetic manipulation of TrkB on the depression-like behavior of mice  
As the number of genetically modified mouse lines increases, adequate behavioral 
measurements of depression-like behavior become more important; MAS is a good basis for this. 
MAS mimics several symptoms of depression and requires alterations in biochemical and 
neurophysiological markers similar to those that occur in depressed patients (Dzirasa & Covington, 
2012). However, the authors do not specify these markers or the etiological basis of depression and 
leave interpretation to the adapters of the model. As Willner and Mitchell (2006) described, a good 
depression model should also exhibit responsiveness to current AD treatments, preferably upon 
chronic administration. Thus, when evaluating the equivalence of a transgenic mouse model to 
depression, pharmacological responses should also be considered. Furthermore, although the 
authors omitted behavioral despair tests from their model, it may be beneficial to add them to the 
test battery because they are currently the only tests that attempt to measure the “mood” of mice. 
Other tests that could be included are those that measure the emotional exploratory behavior of 
mice, as the majority of depressed patients also suffer from anxiety disorders.  
Regardless of the large number of genetically modified mouse lines, genetic studies have not 
clarified the connection between BDNF signaling and depression. BDNF ligand-dependent transgenic 
mice models have not facilitated the characterization of the depression-like phenotype. Moreover, 
full-TrkB receptor  KO mice are  not  viable,  so  other  approaches are  needed.  TrkB.T1 knock-in  mice 
overexpress a natural form of the truncated TrkB receptor in neurons, leading to decreased BDNF-
TrkB signaling. Similar to BNDF(+/-) mice, these mice have impairments in memory, and the 
antidepressant-like effects of ADs are blocked in TrkB.T1 knock-in mice (Saarelainen et al. 2000; 
2003). These mice have been subsequently backcrossed to other genetic backgrounds, increasing 
interest in their use. In contrast to previous findings, we found that in the new background, these 
mice appear to exhibit depression-like behavior in the FST. The dissimilarity between these two 
phenotypes is primarily due to their different genetic backgrounds, which has been shown to 
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strongly influence the behavior of genetically modified mice (Crawley et al., 1997; Crawley, 2008; 
Holmes et al., 2003a; Metz et al., 2006). Furthermore, in our experiments, the TrkB.T1 mice displayed 
alterations in anxiety-like behavior, decreased interest in novel objects, psychomotor retardation 
during the dark (active) phase and no changes in activity during the light (testing) phase (data not 
shown). When stressed, these animals displayed social withdrawal behavior and decreased appetite, 
and in general, they gained less weight and had significantly decreased BDNF protein levels 
compared  to  the  WT  mice  (Razzoli  et  al.,  2011).  However,  stress  did  not  appear  to  influence  the  
metabolic  hormone  or  cytokine  levels  or  weight  of  these  mice  (Razzoli  et  al.,  2011).  When  these  
findings are compared to the symptomatic modeling of depression in Table 3, the TrkB.T1 mouse 
appears to have at least mediocre success as a model of depression-like behavior; these mice exhibit 
social withdrawal when stressed, impairments in learning and memory, decreased 
locomotor/explorative activity and changes in appetite and body weight. However, the results are 
less  encouraging when these mice are  compared to  the MAS criteria,  mostly  because the selected 
tests for MAS are not included in the test battery.  
However, because our studies only encompass basic behavioral phenotyping, additional 
studies are needed before a final conclusion can be made about the suitability of TrkB.T1 mice as a 
depression model. Future studies should include at least test measurements of anhedonic behavior 
(sucrose preference) and changes in corticosterone levels when animals are stressed and/or treated 
with ADs. The responsiveness of these mice to ADs has been examined previously (Saarelainen et al., 
2003). Because these studies were performed with mice of different genetic background and the 
results of the FST differed from previous studies, AD effects should be evaluated further.  
Chen et al. (2005) produced promising new genetic mice with a point mutation in the TrkB 
receptor. This mutation enabled the activity of the TrkB receptor to be turned off at the selected 
time point with a specific kinase inhibitor. This mouse appears to be an ideal model to study the 
effects of the time-dependent inactivation of the TrkB receptor on mouse behavior. However, our 
findings suggest that the “silent” mutation in TrkBF616A mice is not that silent, at least from a 
behavioral point of view. Even a single mutation in the receptor changes its conformation enough to 
change the function of the receptor. Thus, this “ideal” mouse model was not as appropriate as 
anticipated.  
6.3 Role of BDNF in the antidepressant-like effect of glutamatergic drugs 
Heterozygous BDNF KO mice have, at best, a mild depression- and anxiety-like behavioral 
phenotype (Chen et al., 2006; Duman et al., 2007; Li et al., 2010b). As our results confirm, these mice 
are indistinguishable from control animals in the behavioral despair model and yield contradictory 
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findings in tests of anxiety-related behaviors. However, as we and others have reported, the effects 
of the classical ADs appear to be inhibited in the BNDF(+/-) mice, suggesting the importance of BDNF 
for the mechanism of action of the classical ADs (Ibaarguen-Vargas et al., 2009; Saarelainen et al., 
2003). Based on these findings, we sought to determine if glutamate-based drugs, which have been 
shown to have fast and robust antidepressant effects in humans and animal models (Autry et al., 
2011; Berman et al., 2000; Koike et al., 2011; Li et al., 2010a; Machado-Vieira et al., 2009; Maeng et 
al.,  2008;  Popik  et  al.,  2008;  Reus  et  al.,  2011;  Zarate  et  al.,  2006),  have  a  similar  effect  in  the  
behavioral despair test as observed in BNDF(+/-) mice. Surprisingly, we observed that the dissociative 
anesthetic ketamine functioned similarly in both WT and BNDF(+/-) mice to induce an antidepressant-
like effect in the FST. 
AMPA  receptor  potentiators  (e.g.,  LY  392098  and  LY  451646)  have  been  shown  to  have  
antidepressant-like effects in rodent models of depression-like behavior (Bai et al., 2001; Farley et al., 
2010). We observed that exposure to LY 451646 yielded an antidepressant-like effect in both BNDF(+/-) 
mice and WT mice, similar to ketamine. Furthermore, neither ketamine nor LY 451646 appeared to 
have  an  effect  on  BDNF  protein  or  Trk-phosphorylation  levels  in  the  HC  of  WT  or  BDNF(+/-) mice. 
These results indicate that the antidepressant-like effect of glutamate-based drugs may be 
independent from BDNF-TrkB signaling.  
However, our findings are inconsistent with some studies suggesting a connection between 
BDNF signaling and the antidepressant-like effect of ketamine (Autry et al., 2011). What could explain 
the differences in the results of these studies? First, Autry et al. (2011) used a more specific deletion 
of  BDNF  at  a  selected  time  point,  while  our  mice  lacked  half  of  the  BDNF  protein  during  their  
development and adulthood. Thus, only 50% reductions in BDNF protein levels may not be sufficient 
to block the AD effects of ketamine, whereas behavioral responsiveness to classical ADs is more 
sensitive to alterations in BDNF levels. The discrepancies in the results of these studies could also be 
due to differences in ketamine dosage [our dosage of ketamine was more than ten-fold greater than 
that used in Autry et al. (2011)] and different genetic backgrounds. 
Furthermore, in our studies, we observed behavioral changes soon after a single ketamine 
administration but not after longer periods of time. This result is in contrast to previous reports of an 
antidepressant-like effect even two weeks after a single ketamine injection (Koike et al., 2011; 
Maeng et al., 2008; Popik et al., 2008). These differences may also be due to the selected dose and 
genetic background of the mice, as Autry et al. (2011) and Maeng et al. (2008) both observed long-
lasting behavioral effects with smaller doses of ketamine (2.5-5 mg/kg). In retrospect, smaller doses 
of ketamine should also have been examined.  
Another AMPA potentiator, LY 392098, has been shown to regulate BDNF expression in 
primary cultured neurons (Legutko  et al., 2001). Furthermore, Mackowiak et al. (2002) observed that 
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both  acute  and  chronic  injection  of  LY  451646  increased  BDNF  mRNA  expression  in  the  rat  HC.  In  
contrast to these findings, we did not observe a change in BDNF protein levels in response to LY 
451646. However, our study set-up differs significantly from that of Mackowiak et al. (2002); in our 
experiment,  we  used  a  fivefold  higher  dose  of  this  potentiator,  and  we  used  mice  instead  of  rats.  
Most importantly, in our study, animals were sacrificed 60 minutes after the drug injection, whereas 
Mackowiak et al. (2002) sacrificed their animals six hours after drug administration. Potential 
alterations in BDNF levels in whole tissue may only be observed after longer time periods.  
However,  in  practice,  the  use  of  large  doses  of  ketamine  is  not  appropriate  because  of  its  
notable side effects, increased risk of abuse and impracticality for extensive clinical use. Thus, an 
orally  active  and  fast-acting  AD  would  be  highly  beneficial.  A  recent  study  revealed  that  ketamine  
activates the mammalian target of rapamycin (mTOR) pathway (Li et al., 2010a), which is involved in 
protein synthesis and synaptic plasticity (Hoeffer & Klann, 2010). Direct inhibition of this pathway in 
the medial prefrontal cortex (with rapamycin) blocks ketamine-induced pathway activation and the 
antidepressant-like effect of ketamine. Furthermore, imipramine, fluoxetine and ECT did not activate 
this pathway. Because classical ADs enhance neuronal plasticity via BDNF-TrkB signaling, the effects 
of glutamate-based drugs may be channeled through the mTOR pathway. In conclusion, as Cryan and 
O’Leary suggested (2010), this pathway could be the target for new, fast-acting ADs. 
6.4 Long-term behavioral effects of fluoxetine exposure in postnatal and adult mice 
ADs have controversial effects on adult depression-like behavior in rodents when given during 
early life; postnatal treatment with clomipramine produces lifelong depression- and anxiety-like 
behavior in rodents. Similarly, SERT-KO mice have been shown to have a depression- and anxiety-like 
phenotype. These behavioral phenotypes have been suggested to be the result of serotonin-induced 
overactivation of presynaptic 5-HT1A-autoreceptors. The findings of Gross et al. (2002) support this 
hypothesis by demonstrating that the 5-HT1A receptor is required during postnatal exposure to 
drugs to induce adult anxiety-like behaviors. In this study, we observed that postnatal treatment with 
fluoxetine (PNF) induced a decrease in weight and activity-related parameters. Furthermore, no 
changes in anxiety-related behaviors were observed, and in contrast to the previous findings, PNF 
decreased immobility time in the FST. However, the dosage and time period of fluoxetine treatment 
may be responsible for the differences between the present and previous findings.  
Encouraged by the finding that adult fluoxetine treatment can induce developmental-like 
plasticity and recover impairments induced by early fluoxetine exposure (Maya Vetencourt et al., 
2008),  the  PNF-treated  mice  were  treated  with  fluoxetine  as  adults.  We  observed  that  these  ADF  
mice  appeared  to  recover  from  some  PNF-induced  changes;  the  weight  of  the  animals  was  
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normalized, as were some but not all of the behavioral alterations. Early fluoxetine treatment might 
interfere with the formation and function of the neuronal network, leading to permanent behavioral 
changes. However, the rescuing effect of fluoxetine in adulthood may result from the reactivation of 
developmental-like plasticity and reorganization of the neuronal network. Furthermore, it is unclear 
if SSRIs have permanent effects in humans if exposed during neonatal or early postnatal life (Nulman 
et al., 1997; 2002; Wisner et al., 2009). In particular, long-term influences should be studied. 
However, the possible long-term influence of the SSRIs should be taken into account when the 
pharmacotherapy of children and pregnant women are evaluated. In conclusion, these findings 
suggest that even if there is a risk of permanent behavioral and neurobiological changes with early 
SSRI treatment, these changes may be reversible.  
Stressful and fearful life events can produce long-lasting pathological fear responses in both 
mice and humans, and these reactions can be erased by exposure therapy (Bisson & Andrew, 2007). 
This fear erasure effect is usually not permanent, and fear reactions return after a period of time. 
However, when performed during the critical period of development, extinction training has been 
shown to be permanent (Gogolla et al., 2009; Kim & Richardson, 2010). Because fluoxetine opens 
critical period-like plasticity in the adult rat visual cortex, we investigated whether this compound 
could also open a similar type of plasticity in fear circuits. We determined that treatment with 
fluoxetine in conjunction with an environmental stimulus (extinction training) enabled permanent 
fear extinction when employed before and, more importantly and relevant from a clinical perspective, 
after a fearful experience. Moreover, extinction training or fluoxetine treatment alone did not induce 
permanent fear erasure. These results also indicate that BDNF plays a role in this fluoxetine-induced 
recovery because the effect of fluoxetine was blocked in BDNF(+/-) mice. In conclusion, our results 
suggest that, as in the visual cortex, fluoxetine can also open developmental-like plasticity in fear 
circuits, leading to permanent fear extinction. However, for long-lasting effects, both drug treatment 
and exposure therapy are needed. These findings emphasize the clinical necessity of both drug 
treatment and psychotherapy for the treatment of depression.   
6.5 New ideas and future studies 
In this thesis, we examined the importance of BDNF-TrkB signaling in the effect of 
antidepressant action and depression-like behavior. We observed that mice with blunted TrkB 
signaling (TrkB.T1, dominant negative) displayed indifference to the surrounding environment, 
indicating potential depression-like behavior. However, as mentioned previously, the behavioral test 
battery lacked some important tests, including anhedonia models. Responsiveness to stress and 
classical  ADs remain to  be examined in  future studies.  We also observed that  the NMDA receptor  
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antagonist ketamine and the AMPA receptor potentiator LY 451646 displayed antidepressant-like 
effects in heterozygous BDNF KO mice, indicating a BDNF-independent mechanism of action. 
However, as discussed above, the results of another study indicated the opposite effect (Autry et al., 
2011). Thus, it would be interesting to study these drugs in TrkB.T1 mice to examine their 
relationship with TrkB signaling. 
As we showed, effects of fluoxetine on the reformation of the neuronal network in mice fear 
circuits are dependent on BDNF signaling. Furthermore, in this study, this phenomenon was 
demonstrated only with the SSRI fluoxetine, and the potential effects of other ADs remain uncertain. 
However, as all classes of ADs induce TrkB signaling and therefore increase plasticity (Rantamäki et 
al., 2007), it is likely that these results can be generalized to a wider spectrum of ADs. However, it is 
unclear if this paradigm will also be applicable to ketamine and LY 451646 and other fast-acting ADs. 
Furthermore, as the AD effect of these drugs appears to occur independently of BDNF, it would be of 
interest to determine if ketamine could, via some other mechanism of action, induce plastic changes 
similar to those obtained with fluoxetine. The findings of Sawtell et al. (2003) support this possibility 
by demonstrating that adult ocular dominance plasticity requires the presence of the NMDA receptor. 
Future studies will reveal whether this phenomenon can also be extended to ketamine and other 
non-classical fast-acting ADs.  
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7 Conclusions 
The main aims of this thesis were to characterize the anxiety- and depression-like phenotypes 
of  TrkB  signaling-deficient  mice  (TrkB.T1),  to  examine  the  role  of  BDNF-TrkB  signaling  in  the  
antidepressant-like effects of ketamine and other glutamatergic drugs, to study the network theory 
of ADs in a mouse fear extinction paradigm and to investigate the behavioral effects of adult 
fluoxetine treatment in mice exposed to fluoxetine early in life. Based on the results obtained, the 
main conclusions are as follows: 
I. The phenotype of TrkB.T1 mice is characterized by decreased spontaneous activity, 
indifference to the surrounding environment or novel objects, increased behavioral despair 
and a lack of motivation, with some similarities with BDNF(+/-) mice. Therefore, TrkB.T1 mice 
may serve as a rodent model of depression. 
II. Both ketamine and the AMPA potentiator LY451646 induced antidepressant-like effects in 
WT and BDNF(+/-) mice. Furthermore, neither ketamine nor LY 451646 affected the levels of 
phosphorylated-Trk or BDNF protein. These results indicate that the antidepressant effect of 
glutamatergic drugs may be independent of BDNF-TrkB signaling. 
III. Early postnatal fluoxetine exposure resulted in long-lasting behavioral alterations in adult 
mice. When given again in adulthood, chronic fluoxetine treatment rescued some of these 
behavioral changes. These results demonstrate that ADs may have long-lasting effects on 
infants and children that should be considered when formulating treatment 
recommendations. More importantly, we determined that these changes may be recovered 
with adult AD treatment. 
IV. The initiation of fluoxetine treatment before or after fear conditioning facilitated long-lasting 
fear extinction in adult mice. Furthermore, neither fluoxetine nor extinction training alone 
produced permanent fear memory erasures; both were needed for a long-lasting effect. 
These findings suggest that fluoxetine can also open developmental-like plasticity in the fear 
circuitry of adult mice, leading to the permanent reformation of fear responses.  
Taken as a whole, these findings strengthen the previous hypothesis that BDNF and TrkB signaling 
are involved in phenomena associated with depression and, more specifically, to the mechanism of 
action of ADs. Furthermore, the AD fluoxetine, when used in combination with an environmental 
stimulus, can facilitate long-lasting changes in the neuronal network. Finally, our results suggest that 
there might be other fast-acting ADs with a mechanism of action other than BDNF-TrkB signaling.  
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